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The greatest strides in vaccine delivery over the last decade have come primarily from a new 
class of nanoparticulate antigen carrier that focuses on reverse-engineering the pathogen-immune cell 
interaction on the molecular level.  Such “pathogen-like particles”, or PLPs, take an elegant approach to 
biomimicry, attempting to artificially isolate or recreate a pathogen’s natural ability to stimulate a 
targeted immune response. In this work, we focused on the transformation of the probiotic E. coli strain 
Nissle 1917 into an outer membrane vesicle (OMV) platform for TH1-biasing delivery of a variety of 
recombinant antigens.  We hypothesize that by harnessing the natural immunomodulation of the Nissle 
1917 (EcN) bacterium, and pairing this immunomodulation with appropriate vaccine targets that require 
potent TH1-biasing vaccine responses, we can engineer a recombinant antigen delivery platform that 
uniquely enhances antigen-specific immunity through pathogen-mimetic vaccination.  As 
bionanoparticulate PLPs often suffer from requiring multiple boosts and external adjuvants to achieve 
pathogen-mimetic memory responses, we further enhanced our EcN OMV platform with controlled 
release delivery using injectable polymeric microspheres as a transient OMV depot. 
From the immunological characterization of free and encapsulated EcN OMVs’ vaccine 
capability, two vaccine targets were chosen to demonstrate the efficacy of the OMVs as a PLP platform 
for vaccine delivery.  To test the capacity of the OMVs to functionally display and vaccinate against a 
heterologous antigen of viral origin, OMVs expressing a subunit of H1N1 hemagglutinin were produced 
and tested on BALB/c mice.  Not only did the resulting immunological assays for vaccine response show 
great promise for a protective response, generating a 2.6-fold increase in IgG2a:IgG1 titers and a 8.1-
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fold increase in IFN-γ:IL-4 T-cell secretion versus a gold-standard control, but further analysis using 
hemagglutination-inhibition assays demonstrated >50-fold enhancement in cross-strain protection 
against H3N2.  Secondly, to test EcN OMVs’ capacity to direct unique immunomodulation to less 
standard vaccine targets, OMVs expressing the peanut allergen Arah2 were produced as both a 
prophylactic vaccine (for preventing peanut allergy) and an immunotherapy (for treating extent peanut 
allergy).  Using a BALB/c mouse model for peanut allergy sensitization, a free EcN OMV vaccine dose was 
administered prior to sensitization, which following anaphylactic challenge post-sensitization resulted in 
protective survival of 100% of vaccinated mice.  Encapsulated controlled release of lower doses of the 
Arah2-displaying EcN OMVs administered following sensitization were also successful at protecting 
>50% of mice from some level of anaphylaxis post-challenge while minimizing side-effects relative to 
traditional sublingual immunotherapy. 
 The engineering and in vitro/in vivo testing of EcN OMVs as vaccine antigen carriers 
demonstrated promising efficacy as a pathogen-mimetic platform for protective immunomodulation.  
Successful testing with a variety of recombinant antigens provides the foundation upon which further 
development of the EcN OMV platform can lead to a promising host of PLP vaccines. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Vaccine Immunology 
While a full review of human immunology is not required to understand the basic principles of 
vaccine engineering as it pertains to this project, a simple review of the basic cells and factors involved 
will be useful.  Indeed, for the purpose of this work, the classical understanding of the development of a 
simple response to a bacterial pathogen, which ultimately is the exact response a traditional vaccine 
aims to replicate1–3, will suffice.  Upon introduction of a foreign material, the injection site becomes 
inflamed, either due to tissue damage and/ or stress (facilitated by many common chemical additives, or 
adjuvants, used in vaccines today) or innate pathogen recognition by tissue-resident immune cells such 
as mast cells or macrophages (leading to the secretion of pro-inflammatory cytokines)1.  This facilitates 
recruitment of additional phagocytes, such as monocytes and neutrophils, which in the case of infection 
would help clear up the site but in the case of vaccines primarily serve simply to sustain the 
inflammation3,4.  The immediate responders to and mediators of this inflammatory response comprise 
innate immunity1.  This inflammation in turn promotes the activation of dendritic cells, which pick up 
antigens from the infecting agent and deliver them to lymphoid tissue3,5.  In the lymph nodes, dendritic 
cells present their antigens to naïve CD4 T-cells, which respond if they have T-cell receptors specific to 
the antigens.  These antigen-specific CD4 T-cells then go on to activate antigen-specific B-cells, which 
results in the secretion of antibodies specific to the pathogenic antigen.  Depending on a variety of 
factors that occur within the lymphoid tissue during this process, CD4 T-cells may also go on to activate 
antigen-specific cytotoxic CD8 T-cells (which help control intracellular pathogens) and facilitate the 
transformation of B- and T-cells into memory cells3,6.  This secondary response, comprising adaptive 
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immunity1, effectively assures a pathogen-clearing response while additionally, and more importantly 
for vaccination, ensuring that subsequent exposure to the same pathogen will not require the 
comparatively lengthy process of “educating” adaptive immune cells3.  
 For the purpose of the following discussion, the most important takeaway is as follows.  During a 
successful immune response to a classical pathogen infection, a variety of innate and adaptive immune 
cells have to 1) be stimulated, 2) interact with an antigen, and 3) develop lasting antigen-specific 
memory.  Simply put, an effective vaccine directly or indirectly interacts with the immune cells described 
above to achieve a similar response. 
 
1.2 Recombinant Subunit Vaccines and the Adjuvant Fallacy 
Vaccine design has, in principle, come a long way from Edward Jenner’s work3 over two centuries 
ago, where a vaccine was the simple concept of exposing the immune system to a pathogen that 1) 
facilitated an improved immune response when later challenged naturally by an infection of that same 
or related pathogen, and 2) did not cause a similar or worse infection of its own.  Vaccines now, at their 
most rudimentary level, attempt to balance two crucial factors that were key in even Jenner’s original 
smallpox vaccine: pathogenic identity and immune stimulation.  The search for stronger adjuvants that 
can direct immune responses down specifically biased paths represents the field’s advances and goals 
concerning the latter6–8.  The recombinant subunit approach to vaccines, on the other hand, best 
represents advances made concerning the former9. 
 The principle of recombinant subunit vaccines is simple to grasp but often difficult to apply to 
complicated pathogens.  On a molecular level, immune responses do not target pathogens as a whole 
but instead develop incredibly refined affinity for specific pathogen-related molecular targets.  The 
innate immune system has a range of targets it’s evolved to recognize without any additional “training”,  
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and they mostly come in the form of what are called pathogen-associated molecular patters, or 
PAMPs1,10.  Toll-like receptor (TLR) agonists such as bacterial lipopolysaccharide (LPS) are the most 
prevalent examples11,12.   The adaptive immune system, on the other hand, has a far more elegant and, 
appropriately, adaptive capacity for molecular target identification.  Foreign bodies deemed to be non-
host are probed against a potential-target space whose diversity has been estimated to exceed 1011 
possible targets for B-cells and up to 1018 targets for T-cells3.  Exquisitely organized directed evolution 
that plays out within lymph node follicles during infection (or vaccination) directs selection of immune 
cells that recognize prominent and specific subunits of pathogen-associated molecules, or antigens, and 
directs an adaptive immune response against the pathogen in question by seeking out those antigens.  
Recombinant subunit vaccines therefore follow a simple strategy: if one can isolate the best antigens 
from a pathogen, then attempting to formulate a medicinal product out of a complicated, mostly-intact 
organism can be replaced by a simple mixture of several recombinant protein products. 
 While there have been notable successes in taking recombinant subunit vaccines beyond the lab 
and into clinical applications, especially as related to conjugate vaccines for applications ranging from 
meningitis to Haemophilus influenzae13,14, the significant challenge facing the field revolves around the 
crucial trade-off in attempting to dramatically simplify the development of antigen-specific immune 
responses.  Indeed, the recombinant subunit antigens are almost always very poorly immunogenic, 
requiring some additional adjuvanting material to be added to direct the immune system to take notice 
of the vaccine antigen9.  Unfortunately, both classic adjuvants such as aluminum hydroxide compounds 
and more cutting-edge squalene-based adjuvants such as Novartis’ MF597,15 are inadequate attempts at 
fully engaging the immune system in a meaningful way.  The reason is simple: adjuvanting materials 
primarily work by generally aggravating injection-site tissue to recruit immune cells, rather than 
mimicking pathogenic infection and engaging the highly-evolved antigen-selection machinery described 
above via directed immunostimulatory antigen presentation to adaptive immune cells6,8,16.  The result is 
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often an immune response typified by poor memory, only partially-evolved antibody selection and 
hypermutation, and minimal cellular immunity induction. 
This problem is further compounded by a need to direct the immune system in more subtle 
ways for certain pathogens.  Not all immune responses are created equal, and stimulating the “wrong” 
immune response in a vaccine can render it essentially useless2,3.  While modern immunology tries to 
avoid gross simplifications concerning “branches” of the immune system specific to pathogen types, the 
simple fact is that certain pathogens require certain tailored immune responses to be effectively 
suppressed and cleared.  As an example, the adjuvant aluminum hydroxide7,17 stimulates a balanced 
immunological interplay between responses dominated by the TH1 and TH2 subtypes of T-cells, which is 
ideal for many pathogens such as poliovirus and meningococcal meningitis.  Successful immune 
responses against many other pathogens, however, requires the generation of a more biased immune 
response, such as TH1 bias for combatting tuberculosis or malaria
18,19.  While dozens of excellent antigen 
targets for tuberculosis and malaria vaccines have been identified over the past several decades, the 
inability to tie appropriately biased immune responses to their recombinant subunit forms is essentially 
the largest barrier to making progress in vaccine development.  Indeed, unless more advanced means of 
tying specifically tailored immune responses to recombinant subunit antigens can be discovered, the 
technology itself can expect to continue to only produce incremental advances rather than 
breakthrough preventative therapies4,6,9. 
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1.3 Pathogen-like Particle Vaccines 
Targeted vaccine delivery is a viable alternative to adjuvanting materials, focusing on the cellular- 
and nanoscale-level presentation/exposure of the recombinant subunit antigens to the immune system.  
This may take the form of liposomal or polymeric particles laden with antigen targeted to lymph nodes 
to facilitate controlled antigen release there, or alternatively might seek to use nanoparticles to deliver 
small recombinant pathogen peptides or even DNA intracellularly to immune cells4,20–23.  Design 
considerations become very similar to that of more classical controlled release and drug delivery 
problems, including biocompatibility, accuracy of targeting, and pharmaceutical delivery kinetics.  Such 
considerations must in turn be appropriately balance with the previously discussed goals of a 
recombinant subunit vaccine in general, such as biased immunity stimulation and immune memory 
induction. 
A subset of this approach is the pathogen-like particle (PLP), which also focuses on targeted antigen 
delivery while simultaneously seeking to replicate the interaction between pathogen and immune cell.  
PLPs usually have several key goals: 1) delivery of recombinant pathogen antigens directly to immune 
cells in a way that mimics what the pathogen itself would do, 2) use of a variety of molecular cues to 
stimulate the immune system without additional adjuvant, and 3) direct stimulation in a way that 
enhances immune system bias most effective in combatting the target pathogen.  While few PLPs are 
currently in use or very close to clinical application9,24, several are moving through clinical trials and all 
represent significant improvements to the current vaccine technology paradigm4,22,25.  These PLPs use a 
variety of techniques to directly deliver and enhance immunostimulation to their antigen.  A 
prototypical PLP is illustrated in Figure 1.1 as an example.  Antigenic moieties may be encapsulated or 
surface displayed in association with a synthetic or biologically-derived material, and are delivered in 
particulate form via various targeting moieties, such as antibodies to B-cell or T-cell receptors.  Delivery 
is supplemented with the release of soluble factors that act as cues for the stimulation of appropriate  
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Figure 1.1: Model pathogen-like particle (PLP).  A prototypical PLP seeks to break down a pathogen into 
its most basic factors, as “seen” by the immune system, packaging soluble antigen and 
immunostimulatory co-factors into a simple synthetic particle , which can be recognizable by immune 
cells via additional surface-presented antigen and/or other moieties that target the PLP to certain 
immune cell surface markers.  Adapted from artwork by Linxiao Chen. 
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immune responses; for example, to facilitate a cellular immunity through T-cell stimulation and TH1 bias, 
the PLP might be designed to co-encapsulate and release IL-2 and IFN-γ.   
Disadvantages of PLPs, much like their design parameters, closely mirror those of current 
advances in drug delivery technology.  As complexity and multimodality of the particle platform 
increases, thus improving its ability to behave like a pathogen, cost and complexity of synthesis increase 
as well.  Additionally, singular targeting modalities and co-factors come very short of harnessing the true 
complexity of biological organisms they seek to replace.  The most advanced PLPs being developed 
today rarely use more than two or three pathogen-like moieties; a simple pathogenic organism such as a 
bacteria, as a point of contrast, displays hundreds of different protein and lipopolysaccharide modalities, 
many of which have some interaction with the immune system at least in minimal capacity.  Thus in 
their current form, most PLPs will likely be limited to tailored applications where cost, complexity, and 
scalability are less of an issue. 
It is important to note that much of the preceding discussion is tailored around the concept of a 
PLP being exclusively or at least partially synthetic.  In reality, the most successful PLPs to date are 
actually entirely biologically-derived.  Virus-like particles such as those used in Gardasil® (for human 
papilloma virus)24 and Mosquirix® (for malaria)18 have achieved impressive results by simply attaching 
antigens to the surface of self-assembling viral capsid proteins, which function as mildly 
immunostimulative and naturally-targeted antigen carriers when injected as a vaccine.  While 
production cost, extent of target pathogen applicability, and sufficient efficacy remain very real hurdles 
for such formulations as well, their success makes a compelling case for seeking a middle ground that 
can effectively harness some component of the inherent biological complexity involved in the host-
pathogen response while still refining the concept of vaccine delivery through antigen carriers into a 
feasible application. 
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1.4 Bacterial Outer Membrane Vesicles (OMVs) 
Bacterial outer membrane vesicles, or OMVs, are biological phenomena that occur in gram-
negative bacteria and have potential applications to vaccine engineering as naturally immunoactive 
carrier particles10,26–28.  Under certain conditions – sufficient bacterial culture density to facilitate the 
advantages of quorum sensing and communication, biofilm formation, competition with different 
prokaryotes for resources, interactions with a hostile host environment – bacteria have been shown to 
spontaneously bud off proteoliposomal vesicles from their outer membrane.  The formation of these 
vesicles can involve a fairly dramatic reorganization of the inner and outer membrane to facilitate 
periplasmic leakage and surface component organization, respectively.  The end result is a 
bionanoparticle whose surface is often representative of the biomolecular complexity of its bacterial 
source, and whose interior is filled with soluble components from the periplasmic space.  Naturally 
produced OMVs have been hypothesized to be evolved for the delivery of both signaling agents and 
cytotoxic products, essentially acting as a remote extension of the bacteria itself capable of spreading its 
influence over larger, less localized length scales26,27. 
 The immunology of OMVs is of special interest, as it has been found to be surprisingly complex.  
Recent data demonstrates that OMVs are highly immunogenic despite being entirely non-infectious and 
non-replicative.  The simplest source of such immunogenicity is their exterior composition.  Bacterial 
outer membranes are comprised of a variety of innately stimulatory TLR agonists and, more generally, 
PAMP-rich biomolecules, and such composition is directly reflected in a particular bacteria strain’s 
OMVs10.  Additionally, OMVs seem to be selectively enriched in particularly potent TLR agonists such as 
LPS (acting on TLR 2 and 4), BLP (TLR 2 and 1/2), and flagellin (TLR 5).  Further analysis also reveals the 
internal inclusion of various “vita-PAMPS”, periplasmic components such as dsDNA and ribosomal 
subcomponents that if released intracellularly can induce immunological reactions reflective of 
intracellular infection (by acting through TLRs such as TLR 9 and TLR 13)29.  These moieties are made  
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more relevant when considering studies have shown that OMVs can interact with immune and non-
immune cells alike to deliver such agents by interacting with extracellular receptors via surface contact, 
being internalized via phagocytosis and additional clathrin independent pathways and thus releasing 
factors intracellularly, and even partially fusing to cell membranes10,27.  These delivery routes in turn 
trigger a variety of immunological cascades that have been shown to not only lead to downstream 
engagement of immune reactions, but tend to mirror activation traditionally reserved for active 
intracellular infections.  Such capacity has been pursued as a means to use OMVs as a vaccine against 
their pathogenic source, with an OMV vaccine against meningococcal meningitis currently on the market 
in several countries outside the United States13,30–33. 
 Previous work by our group34,35 and others36 has focused on harnessing this self-adjuvancy 
potential as a potent recombinant vaccine antigen carrier.  The general strategy is fairly simple (Fig. 1.2): 
1) deregulate vesiculation in a bacteria of interest through genetic mutation, thus turning the mutant 
into an OMV “factory”; 2) induce expression of a fusion protein involving an exogenous antigen of 
choice and some moiety that facilitates transport to the outer membrane; and 3) harvest resulting 
OMVs through simple centrifugation.  While we’ve investigated several potential routes of antigen 
delivery from expression in the cytoplasm, the route detailed in this project utilizes the bacterial 
enterotoxin ClyA as its means to transport an antigenic protein subunit to the outer membrane37,38.  As 
we’ve previously reported34, ClyA has the unique capacity to not only facilitate exportation through the 
periplasmic space, but can additionally insert itself in the outer membrane in a fashion that externalizes 
any polypeptide sequence linked via its C-terminus.   
Published work demonstrates that such approaches to incorporating recombinantly expressed 
antigens into OMVs can result in immunostimulatory35 and even protective36 vaccines.  In this respect in 
particular, recent studies by a variety of groups are both illustrative of the promise of engineered OMV  
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Figure 1.2: Generating engineered OMVs from E. coli that surface display exogenous antigens.  E. coli 
genetically modified to overproduce OMVs (such as via nlpI mutation used in this proposal) are 
transformed with a plasmid encoding the appropriate ClyA-antigen fusion, in this case ClyA-GFP.  Once 
transcribed, ClyA co-localizes the chimera to the E. coli outer membrane.  As the bacteria continuously 
bud off OMVs, and the plasmids are designed to be under a high-copy-number promoter, the average 
OMV generated through the induced hypervesiculation will have a substantial number of recombinant 
ClyA-antigen fusions included in its membrane.  Adapted from artwork by Dr. David Chen. 
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vaccines as well as useful in guiding identification of an optimal path forward to rationally harness their 
potential.  Unsurprisingly, some of the most instructive studies of OMV vaccine immunology have come 
from recent attempts to better understand the protective effect of the N. meningitides vaccine, 
particularly the vaccine against serogroup B30,39–42.  This vaccine of particular interest to the vaccine 
community as standard recombinant approaches to vaccinating against serogroup B are largely 
ineffective.  Specifically, molecular deconstruction and immunological analysis of the available OMV 
vaccine (Novartis’ Bexsero®) has yielded two useful insights.  First, the efficacy of the vaccine stems from 
an impressive capacity to capture the natural (and naturally immunostimulative) biomolecular 
complexity of the bacterium it is derived from.  Like many lethal pathogens of interest as vaccine 
targets, N. meningitides presents a complex array of hundreds of immunologically active protein and 
lipid moieties to the immune system during infection, and a myriad of studies have demonstrated that 
while recombinant multivalent antigen presentation does indeed enhance immunological protection, 
the reliance of serogroup B in particular on diverse glycosylated residues ties efficacy of the OMV 
vaccine very strongly to both the content and manner of PAMP presentation.  Specifically, an OMV is 
capable of multivalent presentation of membrane antigens and immunostimulatory TLR-ligands directly 
to APCs in a biomimetic fashion that both naturally enhances vaccine adjuvancy and intrinsically links 
diverse epitope libraries through cross-presentation.  Indeed, detailed molecular analysis of Bexsero 
vaccine components has revealed evidence of strong concentrations of TLR2, 4, and 5 ligands, which 
potently stimulate immune cells even independent of additional adjuvant11,41–44.  This leads into the 
second major insight of these studies: unlike many recombinant formulations, Bexsero and other OMV 
vaccine formulations seem to be capable under the right circumstances of triggering TH1-biased 
responses.  This has been demonstrated in challenge models as well as cellular studies, and while no 
study has yet directly linked this capacity to the inherent superiority of this vaccine formulation to 
relative to other standard recombinant vaccine competitors, it stands to reason that given the reliance 
12 
 
of the immune system on a TLR4-driven TH1-biased response to combat acute meningococcal 
meningitis, this is a non-trivial discovery.   
 To summarize, the unique protection of Bexsero® is illustrative of an OMV vaccine harnessing a 
diverse, immunostimulatory array of bacterial biomolecules to direct a certain type of protective 
immune response, likely one with a TH1-biasing component.  It is important to note that for this 
particular instance, such a finding is more serendipitous than intentional; however, a broadened 
assessment of recent approaches to use OMV vaccines in a more rationally engineered fashion 
continues to highlight similar themes.  Various recent works41,45,46 suggest OMV-derived protection via 
TH1 bias can at least be regularly achieved against a variety of pathogens using appropriate source-strain 
bacteria.  Furthermore, expanded molecular analysis of OMVs shows divergent composition for 
divergent bacterial sources – that is, the source matters when searching for the right bacterial 
biomolecules to get the right stimulation.  For the purpose of engineering OMVs not merely as vaccines 
against their source-strain, but against a variety of displayed exogenous antigens, the selection of 
bacterium needs to be driven less by the pathogenesis of the organism and more by the contribution of 
certain TLR agonists to a TH1 bias. 
Such observations by the field are the first step towards engineering an OMV platform 
biotechnology for recombinant vaccine delivery, which ultimately is the goal of this work.  While 
questions persist about safely regulating and normalizing the endotoxin content of such formulations27, 
host tolerance as a whole has been positive in many animal models10,35,36,47 and a variety of regulatory 
agencies have given the platform their preliminary blessing30.  Perhaps the greatest unknown concerning 
OMVs as vaccine carriers, therefore, is the immunological “black box” they still represent.  Given what is 
known about OMVs as immunostimulatory agents, there is obvious motivation to simplistically optimize 
their potential for directing immune responses without having to attempt to re-engineer them on a 
molecule-by-molecule basis.  Current efforts are more often than not focused on adaptations of 
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bacterial strains already commonly used in microbiology and biological engineering laboratories, as they 
are after all both well-understood experimental entities and already proven to be economical as sources 
of recombinant vaccines and a variety of other therapeutics.  However, one could alternatively argue 
that given the available insight into the importance of the link between the right assembly of bacterial 
immunogens and the right direction of an immune response, it would make better sense to thoroughly 
investigate less mainstream targets for OMV production based on what their OMVs can rationally be 
expected to produce in a self-directed, self-adjuvanted immune response.  Stated another way, if one is 
no longer limited by making vaccines derived from the pathogen vaccine target itself, what then would 
the ideal OMV source look like?  
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CHAPTER 2 
PRODUCTION AND CHARACTERIZATION OF E. COLI NISSLE 1917 OMVS AS RECOMBINANT ANTIGEN 
VACCINE CARRIERS¥ 
2.1 Introduction 
 E. coli strain Nissle 1917 is a probiotic bacteria getting increasing attention from clinicians and 
microbiologists alike48–53.  Probiotic organisms, almost exclusively bacteria, are organisms that, when 
introduced into the native gut flora, have regulatory properties that can be palliative for variety 
digestive problems54.  Establishment of probiotic colonies in the gut have been shown to rebalance 
other native gut fluora populations, act as a competitive barrier to foreign and opportunistic pathogens 
in the intestines, and stimulate upregulation of suppressive factors that can inhibit autoimmunity and 
allergy.  The later phenomenon is one where EcN uniquely excels, and has gained the interest of many 
clinicians who are pursuing it as a dietary supplement capable of treating general irritable bowel 
disease, Crohn’s disease, and even more globalized allergic responses such as food allergy and asthma.  
Indeed, EcN seems to have an intrinsic ability to facilitate a probiotic effect through direct, local 
immunomodulation that can have a host-wide impact48,50,52.   
This ability has in turn piqued the interest of microbiologists, who have investigated the bacteria 
in vitro and in vivo to ascertain what allows it to so potently modulate a host’s immune system.  While 
the picture remains somewhat incomplete, EcN seem to derive their probiotic abilities from targeted 
disruptive interactions with adaptive immune cells (Fig. 2.1a), primarily T-cells but also gut-resident 
dendritic cells and macrophages48,51,55–58.  Several well-known biomolecular factors have their expression  
_________________ 
¥
Reproduced in part with permission from Rosenthal JA et. al, NanoLIFE 2013, 3(3).  Copyright © 2013 World 
Scientific Publishing Co. 
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Figure 2.1: Isolation of Nissle 1917 (EcN) immunostimulatory factors from immunosuppressive 
mechanisms via OMV engineering.  (A) EcN membranous and soluble TLR agonists work together to 
stimulate, overwhelm, and disrupt adaptive immune cell functions, inducing pseudo-anergy and 
tolerance.  (B) By isolating the membrane-bound targeting/stimulating components of EcN’s unique 
adaptive immunity modulation from its secreted factors, and using them to generate bionanoparticles 
that can target immune cells for extracellular and intracellular delivery of immunostimulatory factors, 
EcN’s natural capacity for immunosuppression can be re-engineered to have a potent adjuvanting effect. 
A 
B 
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substantially upregulated in EcN, whose closest relatives within the E. coli species are, interestingly, 
functionally divergent and highly pathogenic strains59,60.  Specifically, membranous, strain-specifically 
glycosylated LPS, flagellin, and mannose-rich BLPs, as well as secreted BLPs and other bacterial assorted 
secreted factors (ASFs), target immune cells and transduce modulatory signals primarily through TLRs 2, 
4, and 548,55.  These signals cause a variety of immunosuppressive effects that directly target the immune 
cells themselves, especially T-cells, such as decreased propensity to enter G2 or M phases and 
attenuated immunostimulatory and inflammatory activity through decreased secretion of cytokines (IL-2 
and IFN-γ) and costimulatory molecules (CD2 and CD28)55,57.  Additionally, direct immunosuppressive 
function is induced by upregulated IL-10 expression and secretion following interaction with EcN.  The 
general resulting mechanism of action theory holds that TLR agonists selectively target EcN to gut-
associated immune cells and induce strong immunogenic responses, which are followed by large-scale 
secretions of soluble immunostimulatory factors.  This combination essentially overwhelms the immune 
cell and induces pseudo-anergy and immunosuppressive pathway activation, which in turn leads to the 
observed immunosuppressive effect. 
In this project, we seek to exploit the immunostimulatory potential of EcN’s primarily 
membranous biomolecular mechanisms while isolating it from the immunosuppressive secretory 
machinery that drives its clinical activity.  EcN has evolved its niche role in gut ecology to be capable of 
strong targeting and induction of immune cells48–62 – while easily overshadowed by its 
immunosuppressive capacity, this uniquely tailored capacity makes it an ideal candidate for an OMV 
source.  Figure 2.1b details mechanistically why this would be the case.  EcN OMVs, due to the 
membrane material they are derived from, can take advantage of strongly transducing a variety of TLRs 
in a specific combination that apparently can strongly activate T-cells.  Additionally, even ignoring the 
advantages that specific multivalent combinations of TLR agonists seem to have in selectively targeting 
certain immune cells, the presence of such TLRs in addition to bactericidal/permeability-increasing 
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protein (BPI) and LPS-binding protein on the surface of macrophages should additionally facilitate strong 
phagocytic interactions with the EcN OMVs.  Of specific interest is predicting the more exact immune 
response generated by such cellular interactions.  Considering the potential for linking antigen delivery 
with strong T-cell targeting and stimulation, in addition to their capacity for robust antigen-presenting 
cell (APC) stimulation and intracellular delivery of bacterial PAMP-rich agonists, a compelling argument 
could be made for likely TH1 bias in an antigen-specific response leading to strong cellular immunity and 
memory3.  As such a response, combined with the scalable and economic production source of E. coli, 
fulfills key elements of an ideal vaccine carrier for stimulating effective responses to a variety of current 
vaccine targets4–6, EcN OMVs warrant investigation as promising candidates for recombinant subunit 
antigen delivery. 
 Herein we report the biomolecular and immunological characterization of EcN OMVs as a 
recombinant vaccine carrier utilizing the model antigen green fluorescent protein (GFP).  Importantly, 
this data will be presented relative to OMVs derived from a standard laboratory K12 E. coli strain, 
JC8031 (EcJ), to highlight the advantages of using EcN as an OMV source strain.  A standard 8-week 
prime-boost vaccination regimen in BALB/c mice resulted in substantial TH1-biased anti-GFP immunity 
characterized by a robust humoral and cellular response.  Further biomolecular analysis revealed that 
this favorable response was at least partly enhanced by enrichment in TLR agonists such as flagellin and 
mannose, which upon further in vitro and in vivo assessment resulted in enhanced inflammation, innate 
and adaptive immune cell recruitment and stimulation, and broad-spectrum TLR activation.  We 
additionally report several other characteristics of the EcN OMV vaccine platform, including the capacity 
to achieve potent anti-antigen immune responses at low doses of antigen and the apparent dependence 
of this immunity on pathogen-mimetic surface display of said recombinant antigens.  
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2.2 Materials and Methods 
2.2.1: Design of Nissle nlpI-mutant JH1 and lpxM mutant JH1-LpxM.  nlpI and lpxM mutations were 
generated using P1 transduction of the nlpI::kan and lpxM::kan alleles, creating strains JH1 (ΔnlpI) and 
JH1-LpxM (ΔnlpIΔlpxM), from the Keio collection63.  Briefly, E. coli Nissle 1917 bacteria were grown 
overnight and incubated with P1 lysates from appropriate Keio single mutants, as described elsewhere64.  
Transduction was performed using 50 mM CaCl2 for 20 min at 37 ᵒC and 1 M Na-citrate for 40 min at 
room temp, and selective plating was done using medium containing 20 mM Na-citrate.  Visual 
characterization was done using a LEO 1550 FESEM, a FEI Tecnai F20 TEM, and an Olympus BX41 for 
SEM, TEM, and fluorescent microscopy, respectively.  Further protein characterization was done using 
BCA assay and Western blot, while LPS was analyzed using a KDO colorimetric assay and proteomics 
were done using the isobaric tag for relative and absolute quantitation, or iTRAQ, method. 
2.2.2: Mouse Immunizations.  Ten groups of ten 8-week old BALB/c mice (Charles River Laboratories) 
each were immunized s.c. with 100 µL of PBS containing purified protein or OMV preparations as 
described.  The ten treatment groups were immunized with, respectively: PBS, 2.5 µg GFP/H1N1 HA, 2.5 
µg ClyA, 2.5 µg GFP and ClyA mixture, 2.5 µg ClyA-GFP/H1N1 HA fusion, 2.5 µg alum and ClyA-GFP/H1N1 
HA mixture (Alyhydrogel®, 1.3% aluminum hydroxide [mass:volume]), and recombinant fluorescent 
equivalents of EcJ+ClyA-GFP/H1N1 HA, EcJ (empty), EcN+ClyA-GFP/H1N1 HA, and EcN (empty).  Two 
doses of vaccine (priming dose and boosting dose) were administered 4 weeks apart.  Blood was 
collected from the mandibular sinus immediately before and 2 weeks after the first immunization, 
immediately before the boosting dose, and at 2 and 4 weeks after the boosting dose.  Terminal 
splenectomies were performed on half (n=5) of all ten groups immediately before administration of the 
boosting dose and on the other half (n=5) following the final blood collection.  The protocol for the 
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animal studies was approved by the Institutional Animal Care and Use Committee at Cornell University 
(protocol number 2009-0096). 
2.2.3: Assessing OMV vaccine immune response.  Standard microtiter ELISA was performed on 
collected serum samples from vaccinated mice in 96-well plates.  Wells were incubated with purified 
GFP overnight, followed by serial dilution incubation with serum.  Secondary antibodies for IgG, IgM, 
IgG1, and IgG2 were subsequently incubated and detected using HRP.  Hemaggluniation inhibition 
assays were run using serum incubations with formalin-neutralized PR8 and X31 virus, and were 
detected via visual inspection of hemagglunination patterns.  ELISA was also used to quantify antigen-
specific T-cell response.  Purified splenic T-cells were cultured for 7 days in complete RPMI, then seeded 
into wells and incubated in triplicate with GFP for 48 h.  Anti-IFN-, IL-4, and IL-10 antibodies were then 
used to detect the presence of stimulated cytokine release.  Further proliferation analysis on T-cells was 
also done on similarly cultured T-cells.  Cultured T-cells were trypsinized, centrifuged at 1000 rpm, and 
diluted to 1X106 cells/mL in complete RPMI, then labeled with CFSE (Invitrogen).  2X105 cells were 
seeded into 96-well plates, incubated with 30 L 100 g/mL GFP, and allowed to proliferate at 37 ᵒC for 
4 days.  FACS was used to assess loss of CFSE in proliferating cells.  Additional in vivo inflammation 
response analysis was done using subdermal injections in BALB/c mice ears (n=4), on which 
histopathology was conducted 30 h post-injection of the OMV samples. 
2.2.4: In vitro analysis of immune cell stimulation by EcN OMVs.  Bone marrow-derived macrophages 
were harvested from BALB/c femur bone marrow, column purified, and cultured in complete RPMI for 7 
days.  Following this, they were plated in 6-well plates, incubated with ClyA-GFP(+) OMVs, and assessed 
for phagocytosis-induced fluorescence and IL-12/4/10 expression via FACS analysis.  T-cell activation via 
OMV-pulsed dendritic cells was assessed using DCs incubated for 2 days with OMVs; coculture was 
conducted with CFSE-labeled T-cells in 24-well plates and proliferative analysis was done 7 days 
following initial seeding.  CFSE-labeled B-cells were assessed identically to antigen-restimulated T-cells, 
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as described previously.  Knock-out macrophages were acquired as generous gifts from Dr. Cynthia 
Leifer, and were stimulated with OMVs for 3 hours prior to media analysis of TNF-α. 
NOTE: Additional Materials and Methods can be found in Appendix I. 
 
2.3 Results and Discussion 
2.3.1: Vaccination using green fluorescent protein (GFP) as a model antigen 
Previously, we reported the successful expression and functional folding of a variety of 
recombinant antigens on the surface of K12 E. coli OMVs by inducing expression of a chimera consisting 
of the antigen fused to the C-terminus of enterobacterial cytotoxin ClyA34, as illustrated previously in 
Figure 1.2.  For the present study, green fluorescent protein (GFP) was selected as the primary model 
antigen for two reasons.  First, GFP’s natural fluorescence allowed simple quantitation of antigen 
content in all vaccine preparations, owing to the ClyA-antigen chimera’s capacity to retain proper 
antigen folding upon outer membrane insertion35.  GFP’s second advantage was its poor 
immunogenicity in mice, which allowed for maximal demonstration of the vaccine carrier’s 
immunostimualtory potential.  OMV overproduction was induced in EcN via genetic knockout of nlpI28,34 
to produce the antigen delivery platform (Fig. 2.2a).  OMVs released by the hypervesiculating EcN 
mutants expressing ClyA-GFP exhibited uniform size and shape while retaining characteristic bilipid 
membrane structure (Fig. 2.2b) and carried fluorescent membrane-bound, surface displayed GFP (Fig. 
2.2c).  To demonstrate the effect of probiotic strain-selection on the immune response, similar GFP-
containing OMVs were produced as a control using non-probiotic K12 E. coli strain JC8031 (EcJ)34,35.  
Western blot analysis confirmed comparable ClyA-GFP content in both OMV preparations (Fig. 2.2d), 
allowing for meaningful comparisons between the two strains’ abilities to trigger an immune response 
against the model antigen. 
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Figure 2.2: EcN nlpI mutant strain produces functional OMVs for recombinant subunit vaccine 
applications.  (A) OMV over-production was achieved in EcN via a marked deletion of nlpI as illustrated 
here on a genetic map of the E. coli genoma, 71.0-71.1 min.  (B) FE-SEM micrographs (left panel) 
demonstrate predominantly uniform size and shape of EcN OMVs, while TEM micrographs (right panel) 
highlight characteristic bilipid membrane.  Scale bars = 200 nm.  (C) Fluorescent micrograph of 
ultracentrifugation-purified OMVs from EcN cultures transformed with ClyA-GFP-contating plasmid.  (D) 
Western blot with anti-GFP antibodies of OMV suspensions from EcN and EcJ cultures transformed with 
ClyA-GFP-containing plasmid. 
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Figure 2.3: Schematic of vaccination regimen for murine model immunization.  At time of initial 
vaccination, n=10 mice were vaccinated; at t=4 wk, n=5 mice were sacrificed for splenectomy, leaving 
n=5 mice to continue the experiment to its conclusion at t=8 wk.  t=0 wk is referred to as the “Pre 
prime” period, 0<t<4 wk is referred to as the “Post prime” period, t=4 wk is referred to as the “Pre 
boost” period, and 4 t 8 wk is referred to as the “Post boost” period. 
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 To test the ability of EcN OMVs to generate a strong adaptive response to GFP, we immunized 
BALB/c mice via subcutaneous injection with formulations of OMVs containing ClyA-GFP and free of 
additional adjuvant (Fig. 2.3).  To ensure the meaningful experimentation relative to a substantially 
competitive positive control, we separately injected vesicle-free ClyA-GFP adsorbed onto an enhanced  
aluminum hydroxide adjuvant delivery system, Alhydrogel®.  IgG titers assayed four weeks after the final 
boost indicated induction of a strong humoral response by both EcN and EcJ OMVs comparable to the 
gold standard of alum (Fig. 2.4a), consistent with previous work35 and reflective of progressive 
generation of a robust response (2.5).  However, IgM titers showed some divergence in the humoral 
responses (Fig. 2.4b), with lower IgM levels generated by EcN OMVs indicating either early class-
switching or a discrepancy in B-leukocyte stimulation by membranous endotoxins.  Further divergence 
could be seen in IgG1 versus IgG2 titers.  The EcN OMVs elicited an IgG2-dominant humoral response 
(Fig. 2.4c and 2.6), which taken together with the relative decrease in final IgM titer suggests induction 
of a TH1-facilitated immune response consistent with heightened cellular immunity stimulation
65.  In 
contrast, EcJ OMVs mirrored the alum-positive control with a larger IgG1 fraction, suggesting a less 
remarkable response more in line with standard adjuvants.  As a result, these data not only indicate that 
the EcN OMVs can function as an effective antigen carrier for stimulating humoral immunity, but 
additionally suggest a strain-dependent advantage conferred by EcN in stimulating a more favorable TH1 
response. 
Further analysis of the mice’s OMV-induced adaptive immunity revealed a favorable T-cell 
response reflective of the EcN OMVs’ divergent humoral response.  Specifically, spleen-derived T-cells 
from mice vaccinated with ClyA-GFP EcN OMVs had proliferation responses to antigen restimulation 
comparable to the alum-positive ClyA-GFP control and significantly greater than that triggered by EcJ 
OMVs (Fig. 2.7a).  This result is generally indicative of a superior immunostimulatory effect on naïve T-
cell populations, and is in direct agreement with the driving hypothesis that the EcN membrane may be  
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Figure 2.4: EcN OMV platform generates robust humoral immune response in mouse model. (A-C) 
Terminal data points from BALB/c mice vaccinated and boosted once with antigen-normalized (or 
protein normalized, as appropriate) doses of purified GFP, ClyA, ClyA+GFP, ClyA-GFP(+) and (-) EcJ 
OMVs, ClyA-GFP(+) and (-) EcN OMVs, ClyA-GFP+Alum, and PBS (n=5).  (A-B) Class-specific anti-GFP 
antibody serum titers.  (C) Ratio of serum titers of IgG1 to IgG2.  (A-C) GFP* data are representative of 
ClyA, ClyA+GFP, ClyA-GFP (-) ECJ and EcN OMVs, and PBS control subjects.  Alum = Alhydrogel®.  
**P<0.001.  All values are given as mean + s.d.   
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Figure 2.5: Progressive generation of humoral immunity by EcN and EcJ OMV vaccines.  (A-B) Serum 
samples from jaw bleeds of all mice participating in the experiment were assayed for GFP-specific (A) 
IgG and (B) IgM at four time points: immediately prior to injection with priming vaccination dose (t=0 
wk), following the priming vaccination (t=2 wk), immediately prior to injection with boosting vaccination 
dose (t=4 wk), and at the termination of the experiment (t=8 wk).  Titers were determined by ELISA.  All 
values are given as mean +/- s.d. 
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Figure 2.6:  Anti-GFP IgG1 and IgG2 serum titers from immunized and boosted mice.  (A-B) Serum 
samples from all mice (n=5) at conclusion of experiment (t=8 wk) were assayed for anti-GFP (A) IgG1 and 
(B) IgG2 titers.  Titers were determined by ELISA.  All values are given as mean +/- s.d. 
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Figure 2.7: EcN OMV platform generates robust cellular immune response in mouse model. (A-D ) 
Terminal data points from BALB/c mice vaccina ted and boosted once with antigen-normalized (or 
protein normalized, as appropriate) doses of purified GFP, ClyA, ClyA+GFP, ClyA-GFP(+) and (-) EcJ 
OMVs, ClyA-GFP(+) and (-) EcN OMVs, ClyA-GFP+Alu m, and PBS (n=5).  (A) Proliferation index of GFP-
restimulated spleen-derived T-cells harvested from end-point subjects, measured via CFSE stain.  (B-D) 
Cytokine secretion levels from cultured, GFP-restimulated spleen-derived T-cells harvested from end-
point subjects.  (A-D) GFP* data are representative of ClyA, ClyA+GFP, ClyA-GFP (-) ECJ and EcN OMVs, 
and PBS control subjects.  Alum = Alhydrogel®.  **P<0.001, ***P<0.05 determined by Tukey’s HSD post-
hoc test.  All values are given as mean + s.d.   
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Figure 2.8:  Divergent induction of cytokine expression in spleen-derived, restimulated mouse T-cells 
by EcN and EcJ OMV vaccines indicates superior cellular immunity potential for EcN OMVs.  (A-D) 
Mouse spleens were harvested (n=5) pre-boost (t=4 wk; A and C) and at the conclusion of the 
experiment post-boost (t=8 wk, B and D), from which T lymphocytes were isolated, restimulated, tagged 
for either IFN-γ (A-B) or IL-10 (C-D) expression, and analysed via FACS.  PMA/Ionomycin was used as a 
positive-stimulation enhancing control.  *P<0.001 determined by Tukey’s HSD post-hoc test.  All values 
are given as mean +/- s.d.   
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privileged as an adjuvant material in its ability to actively target T cells.  Moreover, EcN but not EcJ 
OMVs promoted a similarly dramatic increase in antigen-restimulated T-cell IFN-γ secretion (Fig. 2.7b) 
and expression levels (2.8a-b).  Taken together, these results highlight the ability of EcN OMVs to induce 
a strong cellular immune response, which correlates well with the TH1 response suggested by the 
IgG2:IgG1 ratio.  Depressed IL-4 (Fig. 2.7c) and IL-10 (Fig. 2.7d, 2.8c-d) levels relative to IFN-ɣ further 
support the induction of a favorable TH1-biased response by EcN OMVs.  To date, this level of TH1-
indicative IFN- γ/IL-4 discrepancy has rarely been reported in the literature for adjuvant-free vaccine 
carriers, and never for OMV-based systems.  Importantly, this also sets it aside from standard adjuvants 
such as alum, which produce a mixed TH1/ TH2 response that is often insufficient at leveraging the 
advantage of TH1 immunity against certain intracellular pathogens.  Also of note was the observation 
that IL-10 secretory activity from EcN OMV restimulation was elevated relative to EcJ OMVs and the 
alum-positive control.  Considering the successful induction of elevated T-cell IFN-γ levels, this suggests 
a unique use of IL-10 in a supplementary and indirectly beneficial role in generating a favorable yet non-
detrimental T-cell response, such as influencing a shift in the TH1/TH2 balance while controlling potential 
runaway inflammation66.  Taken together, the model antigen-specific humoral and cellular immunity 
induced by the EcN OMV carriers are indicative both of a protective vaccine response67 and, more 
importantly, a response tuned to be useful in targeting pathogens that are most effectively neutralized 
by the more elusive TH1-biased response
68.  
2.3.2: Biomolecular and immunological characterization of EcN OMVs 
 While superior immunostimulation relative to the non-probiotic K12 E. coli OMVs was in line 
with our central hypothesis concerning EcN OMVs’ derived potential for TH1 bias, we were interested in 
seeing whether more detailed analysis of inherent discrepancies between the two strains’ OMVs could 
further corroborate and add clarity to the initial mouse study’s findings.  We started by attempting to 
characterize the biomolecular composition of the two OMVs.  We began by doing full quantitative  
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Figure 2.9: Proteomic analysis of EcN and EcJ OMVs reveals discrepancies in biomolecular content.  
Total proteomic composition, totaling 756 individual protein residue hits cross-referenced between 
three E. coli proteome databases, is fairly similar between both EcJ and EcN OMVs as a whole (A), with 
divergent outliers being classified as those enriched greater than 5-fold in one OMV relative to the 
other.  (B) PAMP-rich TLR agonists significantly enriched in EcN OMVs relative to EcJ OMVs and relative 
to EcN:EcJ LPS discrepancy (LPS assayed separately). 
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proteomic analysis using protein gel mass spectrometry and isobaric tag for relative and absolute 
quantitation, or iTRAQ.  The results were primarily as expected: the majority of proteins were similarly 
present and in roughly equal quantities within both strains’ OMVs, with several more dramatic 
differences revealed at either end of the spectrum (Fig. 9a).  Of interest, however, was the specific 
enrichment of a variety of well-known PAMP-rich proteins and recognized TLR agonists within the EcN 
OMVs relative to the EcJ OMVs.  The most significantly elevated of the group (Fig. 2.9b) range from TLR2 
agonists BLP and OmpC, to TLR4 agonist OMLP, to TLR5 agonist flagellin.  Intrigued, we additionally 
investigated the most well-known bacterial TLR agonist, LPS, via KDO colorimetric assay.  Surprisingly, 
LPS content was primarily conserved between the two OMVs.  While this makes the proteomic analysis 
more meaningful (as large LPS discrepancies would have left room for argument as to whether any other 
PAMP-related factor could really have made a difference), it also leaves questions concerning 
contributions of differential glycosylation to the divergent immune responses.  In other words, could 
differential levels of glycosylation make up for similar quantities of glycosylated residues?  Glycosyl 
composition analysis using combined gas chromatography/mass spectrometry (GC/MS) readily revealed 
a potential answer (Fig. 2.10a-b).  While KDO remained similar, as did a variety of other glycosyl 
residues, significant differences in heptose:mannose ratio between the two OMVs stood out.  While 
heptose is a primarily immunologically uninteresting sugar often commonly associated with LPS, 
mannose is a primary target of innate immune recognition via macrophages and even complement 
activation, which given the likely density of mannose on the EcN OMV surface could actually facilitate 
interactions with the mannose-binding lectin pathway.  While glycosyl linkage analysis unsurprisingly 
painted a more complicated picture (for which further analysis is currently ongoing), on the surface it 
reinforces the heptose/mannose dichotomy while bringing up additional questions concerning ribose 
and glucose discrepancies.  Regardless, the integrated picture of proteomic and gycosyl analysis helps 
remove a significant component of the “black box” problem of the EcN OMV, pointing at a host of  
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Figure 2.10: Glycosyl composition analysis of EcN and EcJ OMVs reveals additional, immunologically 
relevant discrepancies in biomolecular content.  Glycosyl analysis revealed that both sugar composition 
(C) and linkage (D) was in certain cases equivalently divergent relative to protein composition between 
the two OMVs.   
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immunologically relevant biomolecules whose enrichment likely play a role in the observed 
immunogenicity of the resulting antigen carrier. 
As the most obvious link between the biomolecular analysis results and the immune system 
itself were potential interactions between TLRs and mannose-binding moieties and their respective  
OMV surface ligands, we began experimental observation of the EcN OMV/immune cell interface with 
the innate immune system.  Before refining our analysis to controlled in vitro cell culture, we began with 
immunopatholgy studies.  While on a macroscopic level OMV vaccine inflammation was observed to be 
similar to that of the alum control in duration and recovery time (Fig. 2.11), such observations are not 
necessarily reflective of an adjuvant’s capacity for local immune cell engagement and recruitment.  
Hence, we further explored the capacity of EcN OMV self-adjuvancy to robustly induce an innate 
response via initial dermal inflammation.  Using a subdermal injection model in a BALB/c mouse ear and 
subsequent histological analysis, we assessed the acute inflammation response generated by both EcN 
and EcJ OMVs.  The resulting immunopathology revealed a surprisingly marked difference.  At 30 h post-
injection, EcN OMVs demonstrated the ability to dramatically remodel the dermal tissue, cause local 
vasculature swelling, and recruit dense populations of leukocytes (Fig. 2.12c) relative to a blank PBS 
control (Fig. 2.12a).  Such a reaction is an established sign of an adjuvanting material capable of 
stimulating the required innate immunity activation for a good vaccine response4,7.  EcJ OMVs, on the 
other hand, stimulated a much less dramatic inflammatory response with an equivalent OMV dosage 
(Fig. 2.12b).  Taken together, these data imply that the probiotic strain-dependent nature of EcN OMVs’ 
unique immune response is in part dependent on a strong stimulation of innate immunity, a result well 
in line with biomolecular analysis detailed above. 
Importantly, the strain-variable innate immune stimulation resulted from equivalent doses of 
OMV-bound LPS, generally considered to be the most important innate bacterial immunomodulator10.  
This implies that the immunostimulatory mechanism for the EcN OMVs is not fully dependent on the  
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Figure 2.11:  Inflammation in vaccinated mice is similar between adjuvancy sources Alhydrogel®, EcJ 
OMVs, and EcN OMVS.  Gross inflammation (n=5) was graded 0-3, with 0 being equal to no apparent 
inflammation, 1 being mild redness causing no visible irritation, 2 being moderate redness causing no 
visible irritation, and 3 being moderate-to-severe redness resulting in substantial dryness and scabbing 
as well as evident irritation.   All values are given as mean +/- s.d. 
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Figure 2.12: EcN OMVs induce robust innate immunity stimulation via inflammation enhancement.  
(A-D) Histological sections from BALB/c mice ears injected sub-dermally with equivalent doses of: (A) 
PBS; (B) EcJ OMVs; (C) EcN OMVs; (D) LpxM EcN OMVs.  Mice were sacrificed after 30h.  Increased tissue 
remodeling, vasculature congestion, and leukocyte recruitment (as indicated by arrows) can be seen in 
(B) relative to (A), are significantly enhanced in (C), and are attenuated but not removed in (D). 
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fairly toxic bacterial moiety.  Therefore, we next investigated whether or not direct reduction of LPS-
induced endotoxicity would substantially attenuate the enhanced innate response observed with EcN 
OMVs.  A genetic knockout of the lpxM gene in E. coli inactivates the MsbB lipid A acyltransferase and is 
known to minimize LPS-based endotoxicity69; therefore, lpxM was knocked out in the EcN nlpl mutant to 
generate mutant EcN OMVs (Fig. 2.13) and allow investigation of the influence of LPS on the activation 
of the innate response.  Following identical subdermal mouse ear injections, the previously observed 
immunopathology was partially attenuated but ultimately still reflective of an appreciable inflammatory 
response (Fig. 2.12d and Fig. 2.14).  Thus, a non-endotoxicity-dependent, probiotic strain-dependent 
advantage in innate immunity stimulation is clearly conferred by EcN as an OMV source, likely due to the 
presence of other highly active immunostimulatory membranous PAMPs47 and TLR agonists as 
suggested by the proteomic and glycosyl analysis. 
Analysis of EcN OMV macrophage stimulation, an important cellular component of innate 
immunity, provided additional support for an enhanced probiotic strain-dependent mechanism of innate 
immunity stimulation.  When bone marrow-derived mouse macrophages (BMMs) were incubated with 
equivalent amounts of ClyA-GFP-containing EcN and EcJ OMVs, they internalized a significantly greater 
number of the former (Fig. 2.15a and Fig. 2.16).  These results suggest that the EcN outer membrane is a 
more potent activator of macrophage phagocytosis.  Further analysis of BMM cytokine expression 
profiles following OMV incubation additionally revealed a significant discrepancy in IL-12 and IL-4 
expression induced by EcN and EcJ OMVs (Fig. 2.15b).  Specifically, EcN OMVs stimulated elevated IL-12 
but not IL-4 expression relative to EcJ OMVs, indicating a propensity for EcN OMVs to facilitate TH1 
dominance during the adaptive immunity transition.  This may highlight a synergistic coupling of 
enhanced targeting via superior PAMP-dependent TLR crosslinking and subsequent intracellular delivery 
of membranous and soluble bacterial factors10.  The opposite expression levels induced by EcJ OMVs in 
turn suggests facilitation of a mechanism more in line with TH2 bias
70.  These results corroborate  
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Figure 2.13:  LpxM-mutant EcN OMV generation does not appreciably alter OMVs.  (A) Location of 
lpxM mutation site in the E. coli genome, located at 41.75 min.  (B) Dynamic light scattering 
hydrodynamic z-avg particle sizes of both OMVs.  Formulations assessed in PBS.  (C) GFP fluorescence-
standardized ClyA-GFP(+) vaccine doses of EcJ and EcN  OMVs assayed for total protein content via BCA 
assay.  (D) Western blot with anti-GFP antibodies of OMV suspensions from EcN cultures transformed 
with ClyA-GFP-containing plasmid.  Background coloration altered to improve contrast.  (B-C) *no 
statistically significant difference.  All values are given as mean +/- s.d.   
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Figure 2.14:  LpxM mutation confers quantifiable reduction, but not ablation, of proinflammatory 
OMV response.  (A) BALB/c mice were injected subdermally on each ear with 10 µL of OMV solution.  
After 30h, the mice were sacrificed and their ears were immediately resected and placed in 10% 
buffered formalin.  Immunopathology was rated on a scale of 1-5, 5 representing the greatest extent of 
effacement of normal tissue architecture by the inflammatory response.  Each data point represents a 
representative frame taken from one ear section (n=6).  (B) J774.1 murine macrophage culture was 
incubated for 12h with protein content-standardized OMV doses, following which the culture media was 
collected and analyzed via ELISA for IL-6 content.  (A-B) *P<0.005, **P<0.0001 determined by Tukey’s 
HSD post-hoc test.  All values are given as mean + s.d. 
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Figure 2.15: EcN OMVs induce robust stimulation in macrophages.  (A) Percentage of primary mouse 
bone marrow-derived macrophages (BMMs) positive for GFP after 12h incubation with ClyA-GFP(+) 
OMVs.  (B) Percentage of BMMs expressing cytokines IL-12, IL-4, and IL-10 after 12h incubation with 
OMVs. 
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Figure 2.16:  EcN OMVs stimulate stronger phagocytic responses in macrophages.  (A-B) Primary 
macrophages cultured from BALB/c mouse bone marrow were incubated with variable quantities of 
ClyA-GFP(+) EcN or EcJ OMVs and assayed for fluorescence levels via FACS. (A) FACS analysis; (B) 
summarizing graph.  Masses given represent amount of OMVs added as determined by total protein 
content.  All values are given as mean +/- s.d.   
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previous observations of a TH1-TH2 discrepancy being crucial to the mechanistic benefits conferred by 
using the EcN OMVs. 
 Wanting to more specifically clarify the relationship between potential TLR agonists and 
macrophage activation, we ran additional in vitro studies using TLR and TLR-related pathway knockout  
macrophages.  First, to establish the importance of TLR transduction via OMVs, EcN and EcJ OMVs were 
incubated with MyD88 knockout and wild type mouse macrophages.  The results of a subsequent TNF-α 
assay clearly indicated the importance of the MyD88 pathway for OMV-induced macrophage activation 
(Fig. 2.17).  To begin to parse apart the potential ramifications of the divergent biomolecular analysis, 
we began by noting that both EcN and EcJ OMVs contained the potent TLR4 ligand LPS, while EcN was 
enriched with a variety of non-TLR4 TLR agonists.  Therefore, a simple subsequent test to determine 
whether EcN’s non-TLR4 TLR agonists could make a significant impact on macrophage activation was to 
repeat the assay using TLR4-knockout macrophages.  This time, while both EcJ and EcN OMVs remained 
capable of attenuate macrophage activation, EcN OMVs retained a significantly highly stimulatory 
potential (Fig. 2.17), reinforcing the importance of the noted discrepancies in biomolecular content.  
From there, we expanded our assessment to probe a wider range of TLR knockouts by using 
macrophages where all except one of the TLRs had been knocked out.  As expected, TLR pathway 
activation-dependent luciferase expression revealed that EcJ OMVs seem to activate both mouse and 
human macrophages through TLR2- and TLR4-dependent pathways (Fig. 2.18), though the preceding 
experiment implies a slightly larger discrepancy in the importance of TLR4 for macrophage activation 
itself.  While the results for the EcN OMVs revealed a dramatically different story involving substantial 
activation of a range of TLRs, the magnitude of that activation needs to be tempered by the likely bleed-
over of some TLR5 activation, which is a problem with the particular assay selected.  Regardless, the 
results can be confidently summarized as follows: 1) while EcJ OMVs rely primarily on the TLR4 pathway 
for stimulating macrophages, EcN OMVs supplement TLR4 activation with additional, non-TLR4 MyD88  
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Figure 2.17: EcN OMVs stimulate macrophages via a MyD88-dependent, TLR4-
dependent/independent pathway.  Macrophage TNF-α secretion stimulated by OMV incubation in wild 
type (WT), MyD88 deficient, and TLR4 knockout cell lines.  LPS (0.1 ug) used as a positive control.  
*P<0.005 determined by Tukey’s HSD post-hoc test. All values given as mean + s.d.  
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Figure 2.18: EcN OMVs stimulate macrophages via expanded interactions with diverse TLRs.  
Luciferase expression in TLR knockout macrophages (expression correlates with individual TLR 
activation) incubated with OMVs.  *P<0.005 determined by Tukey’s HSD post-hoc test. All values given 
as mean + s.d.  
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activation; 2) EcN OMVs are potent TLR5 activators, likely owing to their enriched flagellin content; and 
3) EcN OMVs likely stimulate a variety of other TLRs in mice as well as human macrophages, though the 
exact strength and relevance of such activation is unknown at this time. 
Returning to our interest in assessing the nature of the TH1-TH2 discrepancy noted in the initial 
vaccine trial, we noted that an important link between a heightened inflammatory response, likely 
mediated by strong macrophage activation, and the development of a strong adaptive T-cell response 
are antigen-loaded dendritic cells (DCs) that migrate from the site of inflammation to local lymph 
nodes2.  To determine if DC-dependent T-cell activation could benefit from the strain-dependent 
immunomodulation induced by EcN OMVs, we assessed the ability of bone marrow-derived mouse DCs 
(BMDCs) incubated with EcN and EcJ OMVs to induce proliferation in spleen-derived mouse T-cells.  The 
pronounced increase in naïve T-cell activation by BMDCs primed with EcN OMVs (Fig. 2.19a) relative to 
those primed with EcJ OMVs suggests that the selection of EcN as the OMV source improved the ability 
of the OMVs to effectively interface with and stimulate antigen-presenting cells (APCs).  Additionally, 
the ability of the EcJ OMV control to also stimulate T-cells through BMDC-dependent activation, albeit to 
a lesser extent than EcN OMVs, helps rule out the possibility that they caused a DC-dependent T-cell 
suppression48, which would have made conclusions concerning a strain-dependent TH1/TH2-bias 
discrepancy difficult.  Finally, recalling our initial interest in direct OMV/T-cell interactions, we incubated 
the mouse T-cells with the two OMVs in absence of any DC co-stimulation and probed for MyD88 
activation as a simple measure of hypothesized TLR activation.  A Western blot run on T-cell lysate post-
incubation highlights the expected discrepancy (Fig. 2.19b): EcN OMVs trigger enhanced MyD88 
expression relative to EcJ OMVs, in line with the driving hypothesis concerning the EcN-derived 
mechanism of enhanced OMV immunostimulation. 
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Figure 2.19: EcN OMVs effectively stimulate adaptive immune cells.  (A) Proliferation of primary mouse 
spleen-derived T-cells following co-culture with mouse bone-marrow derived dendritic cells pre-
incubated with equivalent amounts of EcJ and EcN OMVs.  RPMI = negative control, αCD3/αCD26 = 
positive control.  (B) Proliferation of primary mouse bone marrow-derived B-cells following incubation 
with OMVs, with or without additional T-cell helper factors.  RPMI* data are representative of additional 
controls αIgM, αCD40, and IL-4.  LPS** data are representative of additional controls αIgM/IL-4 and 
αCD40/IL-4.  (C) Western blot using anti-MyD88 antibodies of T-cell lysates following in vitro incubation 
of primary mouse splenocytes with OMVs.  LPS (10 ug) used as a positive control.  (A-B) ***P<0.005 
determined by Tukey’s HSD post-hoc test.  All values are given as mean + s.d. 
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Further assessment of crucial stimulation of DCs revealed additional insight into the unique 
mechanism being employed by the EcN OMVs to stimulated enhanced adaptive immunity.  Two-photon 
microscopy of extracted lymph nodes was used to confirm that OMVs drained into lymph nodes 
following subcutaneous injection, where they spatially overlapped with adoptively transferred dendritic 
cells (DCs) (Fig. 2.20a-c). These results confirm that the OMV carriers and their delivered antigens are  
available to lymphoid-localized DCs, T-cells, and B-cells3. Subsequent in vitro stimulation of separately 
purified murine splenic DCs revealed that while both EcN and EcJ OMVs substantially upregulated CD86, 
EcN OMVs had a greater capacity to additionally upregulate CD80 as well (Fig. 2.21). This is promising, as 
CD80 has been implicated in modulating regulatory immunity in addition to traditional stimulatory 
cellular immunity71. 
Taken together, the enhanced stimulation of both macrophages and DCs by EcN OMVs builds a 
strong case for a PAMP-dependent mechanism for enhanced activation of professional APCs as a crucial 
component of the robust induction of adaptive immunity to a recombinant antigen.  These data led us 
to consider that the EcN OMVs’ immunomodulatory capability might take advantage of similarly 
improved interactions with the third major APC, namely B-cells.  A capacity for direct B-cell stimulation, 
and thus direct surface-displayed antigen presentation, would also help explain the enhanced cross-
strain protection observed when H1N1 HA was used as a secondary model antigen.  Accordingly, we 
measured induced proliferation of splenic mouse B-cells via incubation with EcN and EcJ OMVs.  This 
analysis revealed that EcN OMVs possessed significant potential for T-cell independent B-cell activation 
due to their ability to stimulate B-cell proliferation in the absence of T-cell helper factors (Fig. 2.19c and 
Fig. 2.22).  Such activation is not uncommon in pathogen infection72, and likely resulted from a 
combination of the presence of EcN PAMPs and OMV nanoscale avidity enhancement21.  Interestingly, 
this phenomenon was in strong contrast to the EcJ OMV control’s ability to activate B-cells, which was 
entirely dependent on the addition of T-cell helper factors IL-4 and anti-CD40.  Such a strong 
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Figure 2.20: EcN OMVs visualized through two-photon microscopy demonstrate intact drainage from 
injection site to lymph nodes.  Representative two-photon microscopy of draining lymph nodes from 
mice (n=3, all groups) injected with PBS (a), fluorescently stained EcN OMVs (b), and fluorescently 
stained EcN OMVs and splenic dendritic cells (DCs) (c). White = collagen, red = OMVs, green = DCs, and 
yellow = OMV/DC overlap.  Arrows denote OMVs (b) or DCs (c). Scale bar = 15 µm. 
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Figure 2.21: EcN OMVs stimulate DCs more broadly than EcJ OMVs.  Flow cytometry analysis of primary 
mouse splenic DC stimulation by EcJ and EcN OMVs (n=3, all groups).  *P<0.01.  All values are given as 
mean + SD. 
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Figure 2.22:  B-cells are activated by EcN or EcJ OMVs via different mechanisms.  Primary bone 
marrow-derived BALB/c mouse B-cells were incubated with various quantities of EcN or EcJ OMVs either 
in the presence or absence of T-cell-derived proliferation induction helper factors IL-4 and anti-CD40.  
*P<0.001, **P<0.01 as determined by Tukey’s HSD post-hoc test.  Masses given represent amount of 
OMVs added as determined by total protein content.  All values are given as mean +/- s.d.   
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discrepancy further highlights the important benefit EcN provides to E. coli OMV antigen carriers, 
providing robust humoral immunity through a supplemental T-cell independent mechanism that can 
work in parallel to, and perhaps even uniquely enhance, the establishment of a TH1-dominated adaptive 
response. 
2.3.3: Additional exploration of EcN OMV vaccine response dependence on dose and antigen 
presentation 
 The vaccination studies in 2.3.1 and resulting in-depth immunological analysis in 2.3.2 left two 
questions unanswered that we decided to probe with additional vaccination studies in BALB/c mice 
again using the ClyA-GFP construct as a model antigen.  First, the results of the inflammation analysis 
left mild concerns related to the potential for detrimental, long-term injection-site side effects of EcN 
OMV vaccination.  To determine whether the advantages of EcN OMV immune activation on the 
cellular-level could be sufficiently maintained while using decreased vaccine doses to attenuate 
enhanced inflammation, a dosing study was done while paying closer attention to the short-term and 
long-term injection-site immunopathology.  Second, several converging observations supported the 
hypothesis that EcN OMVs, and perhaps OMVs in general, that surface display their recombinant 
exogenous antigens can take advantage of the presentation of intact, fully-folded antigen epitope space 
to enhance anti-antigen adaptive immunity.  To test whether antigen externalization actually made a 
significant difference, we repeated the vaccination trial while comparing the results of ClyA-GFP OMVs 
to ssTorA-GFP OMVs, the latter of which uses a well-studied Tat signaling pathway73 to transport 
attached peptides to the periplasmic side of the outer membrane while not enabling membrane 
externalization. 
 The results of the dosing study were straightforward and encouraging.  By varying the dose 
down to two orders of magnitude of the original dose used in 2.3.1, we found that up to a 10-fold 
reduction in vaccine dose could stimulate a similar humoral (Fig. 2.23a-c) and cellular response (Fig. 2.24  
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Figure 2.23: EcN OMV carriers generate strong anti-antigen humoral immunity at more dilute 
vaccination doses.  (A-C) Terminal data points from BALB/c mice vaccinated and boosted once with 
antigen-normalized (or protein normalized, as appropriate) with EcN OMVs and controls (n=5).  (A-B) 
Class-specific anti-GFP antibody serum titers.  (C) Ratio of serum titers of IgG1 to IgG2. (A-C) Alum = 
Alhydrogel®.  **P<0.05 determined by Tukey’s HSD post-hoc test.  All values are given as mean + s.d.   
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Figure 2.24: EcN OMV carriers generate strong anti-antigen cellular immunity at more dilute 
vaccination doses.  (A-C) Terminal data points from BALB/c mice vaccinated and boosted once with 
antigen-normalized (or protein normalized, as appropriate) with EcN OMVs and controls (n=5).  (A) 
Proliferation index of antigen-restimulated spleen-derived T-cells harvested from end-point subjects, 
measured via CFSE stain.  (B-C) Cytokine secretion levels from cultured, antigen-restimulated spleen-
derived T-cells harvested from end-point subjects.  (A-C) Alum = Alhydrogel®.  *P<0.005 determined by 
Tukey’s HSD post-hoc test.  All values are given as mean + s.d.   
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a-c).  Additionally, gross inflammation observation (Fig. 2.25) demonstrated that the 10-fold reduction 
was all that was required to almost entirely eliminate injection site redness that lingered beyond the 
first few days in the original trial.  We decided to do histological analysis of the injection site as well (Fig. 
2.26), to ensure that gross inflammation observation correlated with a decrease in lasting tissue-level 
effects.  Specifically, we stained for fibrin deposition using Masson’s trichrome, which clearly 
demonstrated that the 10-fold dose reduction maintained immune cell recruitment while attenuating 
fibrous deposition that could lead to undesirable scaring in a human subject.  Given these results, it is 
safe to conclude that dose optimization, combined with more refined techniques such as LPS 
endotoxicity mutations as described in 2.3.2, can likely overcome any substantial side effects generated 
by an EcN OMV vaccine. 
 For the second study focusing on ClyA versus ssTorA as an antigen transporter, a similar parallel 
could be drawn between the results of the humoral (Fig. 2.27) and cellular (Fig. 2.28) immune response 
analysis and those presented in 2.3.1, with one significant difference.  As expected, the EcJ and EcN 
OMVs containing ClyA-GFP performed similarly to their identical experimentation presented previously.  
Concerning EcJ ssTorA-GFP, there was no statistically significant change in humoral or cellular response, 
suggesting that antigen internalization versus externalization for the EcJ OMV is not a very important 
factor.  The same could not be said for the EcN OMV.  The general humoral and cellular response, 
reflected by total IgG and T-cell proliferation stimulation, was clearly attenuated as a whole, implying 
that surface antigen presentation is important for the antigen delivery mechanism used by the EcN 
OMV.  Moreover, delivering the GFP to the EcN OMV using ssTorA resulted in the removal of the 
favorable IgG2:IgG1 and IFN-γ:IL-4 ratios, implying a reduction in both functional humoral immunity 
(reduced opsonizing/neutralizing antibodies) as well as a loss of TH1 bias.  Additional experimentation 
may be needed to better support the apparent conclusion, but the results of this experimentation 
reinforce two phenomena previously suggested by the studies in 2.3.1 and 2.3.2: 1) EcJ and EcN, despite  
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Figure 2.25: Long-term inflammation study in mice demonstrates removal of injection-site side 
effects.  (A-C) End-point inflammation at the injection site of the vaccinated mice (n=5, all groups).  
Compared to an alum + killed E. coli positive control (A), low-dose OMVs remove potentially damaging 
bacterial factor-mediated inflammation (B) relative to an alum-antigen control (C).  (D) Inflammation 
was tracked over a course of 90 days, and scored 0-5 (0 being completely normal, 3 being noticeably 
inflamed with evident hair loss, and 5 being permanently scarred with obvious fibrosis, complete hair 
loss, and clearly detrimental discomfort). All images are representative of experimental groups (n=5).  
Arrows note major marker of inflammation. 
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Figure 2.26: Long-term immunopathology study in mice demonstrates removal of injection-site side 
effects.  ).  (A-C) While the alum + killed E. coli control generated substantial fibrosis (blue) (A), low-dose 
OMVs eliminated mild fibrosis at the injection site (B) relative of the alum-antigen control (C) after 8 
weeks following initial vaccination.  (A-C): all images are representative of experimental groups (n=5).  
Arrows note major marker of inflammation. 
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Figure 2.27: EcN OMV carrier’s enhanced anti-antigen humoral immunity is partially dependent on 
antigen surface presentation.  (A-C) Terminal data points from BALB/c mice vaccinated and boosted 
once with antigen-normalized (or protein normalized, as appropriate) with EcN OMVs and controls 
(n=5).  (A-B) Class-specific anti-GFP antibody serum titers.  (C) Ratio of serum titers of IgG1 to IgG2.  (A-
C) Alum = Alhydrogel®.  *P<0.005, **P<0.05 determined by Tukey’s HSD post-hoc test.  All values are 
given as mean + s.d.   
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Figure 2.28: EcN OMV carrier’s enhanced anti-antigen cellular immunity is partially dependent on 
antigen surface presentation.  (A-C) Terminal data points from BALB/c mice vaccinated and boosted 
once with antigen-normalized (or protein normalized, as appropriate) with EcN OMVs and controls 
(n=5).   (A) Proliferation index of antigen-restimulated spleen-derived T-cells harvested from end-point 
subjects, measured via CFSE stain.  (B-C) Cytokine secretion levels from cultured, antigen-restimulated 
spleen-derived T-cells harvested from end-point subjects.  (A-C) Alum = Alhydrogel®.  *P<0.005 
determined by Tukey’s HSD post-hoc test.  All values are given as mean + s.d.   
 
 
 
  
58 
 
both being E. coli-derived OMVs, stimulate antigen-specific immunity through divergent pathways, and 
2) antigen surface presentation is not only a potential advantage of our OMV antigen carrier platform in 
general, but may be intrinsically tied to the observed favorability of the EcN OMV vaccine response. 
2.4 Conclusions 
 EcN OMVs demonstrated substantial promise as TH1-biasing recombinant vaccine carriers.  
Initial testing using GFP as a model heterologous recombinant antigen demonstrated potent anti-
antigen immunity, both humoral and cellular, that is indicative both of protective efficacy thorough bias 
resulting purely from self-adjuvancy; taken together, this provides ample evidence for investigation of 
applications in vaccine challenge models.  Intriguingly, concerning the desire to create a pathogen-like 
particle that provides targeted self-adjuvancy with its delivery directly to innate and adaptive immune 
cells, the EcN OMVs benefited from a variety of molecularly-directed avenues of immune cells 
stimulation that appeared unique to the source strain EcN.  This is meaningful in directing further OMV 
engineering: if molecular mechanisms of pathogenicity can be harnessed in OMVs to create pathogen-
mimetic routes of similarly-biasing self-adjuvancy, then selection of OMV source strain may be an 
extremely significant selection.    
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CHAPTER 3 
ENHANCEMENT OF ECN OMV VACCINES WITH SELF-BOOSTING CAPACITY GENERATED BY 
CONTROLLED RELEASE FROM INJECTABLE POLYMERIC MICROSPHERES 
3.1 Introduction 
 So far, we’ve demonstrated the creation of a new type of PLP, the EcN OMV, for enhanced 
recombinant subunit antigen vaccine delivery.  However, this vaccine carrier only improves on the 
capacity of our vaccine delivery to stimulate antigen-specific immunity on a one carrier-one immune cell 
level.  Assuming that this is the only level on which a pathogenic infection drives an immune response 
neglects one of the more remarkable components of an immune response: its dynamic development 
through time evolution. 
 Even assuming ideal immunomodulatory capacity, the difference between the course of 
immune system exposure to a classical vaccine and that of an actual pathogen during infection are fairly 
dramatic (Fig. 3.1a)1.  While there is no denying that almost every success story for vaccines relies on 
ignoring this discrepancy, it would be foolish to state that a real need in many vaccine targets is 
enhanced and broader immune memory without attempting to address the full, progressive immune 
response required under natural conditions to “train” the adaptive immune system.  Put simply, if the 
problem is that adaptive immunity is not being sufficiently trained by a vaccine, perhaps the time course 
in which it is trained is the real problem. 
Recalling that the goal of this project is to use the EcN OMV to create a holistic pathogen-
mimetic vaccine, it seems an obvious additional step to develop some way to engineer controlled 
release of the antigen carriers that can mimic how the immune system naturally learns to combat real 
pathogens.  The concept of controlled release of recombinant subunits is not new, and has been 
attempted previously and currently by both human and veterinary medicine to enhance the potency  
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Figure 3.1: Combinatorial controlled release can create pathogen-mimetic vaccines.  (A) Classical 
vaccination/boosting antigen delivery stands in stark contrast to the time period of pathogen antigen 
delivery by an actual pathogen infection.  (B) By combining several different controlled release schemes, 
all present in an initial injection, a more complex antigen delivery timeline can be generated to much 
more closely mirror that of an actual infection. 
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and memory induction of simple vaccines.  In contrast to such efforts, however, we propose the use of 
rationally designed kinetic release profiles that do not merely seek to prolong the exposure of the 
immune system to a pathogen, but specifically mimic ideal pathogen loads found to be successful in 
developing naturally potent immunity.  To achieve this, we are interested in generating polymeric OMV-
encapsulating microsphere libraries containing release kinetic “modules” that can be mixed and 
matched to achieve complex, pathogen-mimetic release profiles in single-dose injections. 
The core concepts of our design should be simple and readily manipulated to model our desired 
release profiles.  Ideally, we aim to create microspheres capable of the following release kinetics74–76: 
 
Type I: Zero order: Qt0 = Q0 + K0t 
Type II: First order burst: Qt1 = (Q0-K1) + K1e
K2t (K1 > 0 , K2 >0) 
Type III: First order delayed burst: Qt1 = (Q0-K1) + K1e
K2t (K1 < 0 , K2 <0) 
Where: 
  Qt1, Qt2 =cumulative amount of encapsulated OMVs released at time “t” 
  Q0 = initial amount of OMVs 
  K0, K1, K2 = release rate constants 
  t = time (in days) 
 
These simple equations, which can be fit for individual microparticle formulations through appropriate 
in vitro release studies, can be combined to achieve complex global release profiles.  One can imagine, 
therefore, where several homogenous batches of microsphere-encapsulated OMVs are mixed in 
variable ratios to produce controlled release vaccines custom-tailored to individual pathogens, an 
example of which is illustrated in Figure 3.1b using a governing balance equation: 
 
  Qbody = Qt - Ct 
Where: 
  Qbody = total amount of OMVs in the body at time “t” 
  Qt = ΣQt0 + ΣQt1 + ΣQt2 
  C = OMV clearance rate constant 
  t = time (in days) 
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 To come as close as possible to this goal without requiring complex polymeric engineering 
approaches, we opted to manipulate well-characterized resomers of poly(lactic-co-glycolic acid), or 
PLGA.  PLGA is an attractive material for our desired controlled release applications, as it is already FDA 
approved and its release kinetics are tunable through a variety of parameter modulations.  Additionally, 
there is some precedent for using PLGA as microspheres to encapsulated nanoparticles for controlled 
release applications using double emulsion preparation methods75-76. 
 Herein we report the production and immunological characterization of two controlled-release 
formulations of PLGA microsphere-encapsulated EcN OMVs.  By varying the double emulsion conditions 
of 50:50 PLGA resomers, we were able to create both zero-order and step-wise release spectrums, 
thereby achieving constant and multi-boost delivery of OMVs in vitro.  While only the first step in 
creating truly pathogen infection-mimetic delivery, we nonetheless assessed these release modalities in 
a BALB/c mouse model to see if controlled release of OMVs removed the requirement for multiple 
injections of priming and boosting to achieve a potent response, as well as whether or not these first 
steps at enhancing vaccine memory through pathogen-mimetic timescale control were successful.  
Ultimately we found that humoral immunity was increased over 100-fold and TH1 biasing was 
maintained with a single dose of either controlled release injection, and that the two release schemes 
had variable effects on enhancing memory responses that were indicative of a favorable increase in 
vaccine viability, though further study is required to better elucidate the functional effects on post-
vaccination immunity. 
3.2: Materials and Methods 
3.2.1: PLGA microsphere synthesis.  OMVs were emulsified in a dichloromethane solution of poly(lactic-
co-glycolic-acid) (PLGA), 50:50 (MW 24-38 kDa), for 10-120 seconds using a handheld homogenizer at 
5000-18000 rpm (VWR Disperser VDI12, Dispersing Tool S12N-5S).  Subsequently, this solution was 
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emulsified in 1%-10% polyvinyl alcohol (PVA) in aqueous solution, ultimately generating two populations 
of microspheres: 2-5 µm low-porosity and 15-30 µm high-porosity microspheres respectively.  Particles 
were harvested via centrifugation (5000g, 5 min, 4°C) following evaporative stirring in 0.3% PVA for 3 
hours.  Microspheres were then washed with deionized water and lyophilized following resuspension in 
an aqueous glucose buffer. 
 
3.2.2: OMV stability studies.  EcN OMVs suspended in PBS were tested for stability at -20-37 °C, pH 5.4-
9.4, and under 1000-10000 rpm of stress.  Trials were conducted over a 60 day period with regular 
sampling using DLS measurements; signal counts within the 80-200 nm range were considered indicative 
of intact OMVs, while counts outside of this range were considered indicative of degraded OMVs.   
 
3.2.3: In vitro release studies of microsphere-encapsulated OMVs.  0.1 mg microspheres were 
suspended in 1 mL PBS and gently rotated at 37 °C for 50 days.  At daily intervals up to 21 days (and 
weekly following), 100 uL samples of supernatant were taken and assayed for 1) protein content using a 
BCA assay (Thermo Scientific), and 2) intact OMVs using TEM.  These findings were correlated with SEM 
micrographs of degrading microspheres and in vivo assessment of microsphere degradation (using 
subcutaneous injection of DY-700 [Dyomics] dyed PLGA microspheres visualized under an OV100 
fluorescence imager [Olumpus]).  BALB/c mice were injected subcutaneously with 1 mg of particles for 
in vivo fluorescence correlation studies. 
 
3.2.4: Mouse Immunizations.  Five groups of five 8-week old BALB/c mice (Charles River Laboratories) 
each were immunized s.c. with 100 µL of PBS containing purified protein or OMV preparations as 
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described.  The five treatment groups were immunized with, respectively: 2.5 µg GFP, 2.5 µg alum and 
ClyA-GFP mixture (Alyhydrogel®, 1.3% aluminum hydroxide [mass:volume]), and recombinant 
fluorescent equivalents of EcN OMVs displaying ClyA-GFP, either freely dispersed in PBS, encapsulated in 
zero-order microparticles, or encapsulate in multi-boost microparticles.  Two doses of vaccine (priming 
dose and boosting dose) were administered 4 weeks apart for the free OMVs; encapsulated OMVs were 
injected only once at the beginning of the experiment.  Blood was collected from the mandibular sinus 
immediately before and 2 weeks after the first immunization, immediately before the boosting dose, 
and at 2 and 4 weeks after the boosting dose.  Terminal splenectomies were on all five groups 
immediately following the final blood collection.  The protocol for the animal studies was approved by 
the Institutional Animal Care and Use Committee at Cornell University (protocol number 2009-0096). 
 
3.2.5: Assessing OMV vaccine immune response.  Standard microtiter ELISA was performed on 
collected serum samples from vaccinated mice in 96-well plates.  Wells were incubated with purified 
GFP overnight, followed by serial dilution incubation with serum.  Secondary antibodies for IgG, IgM, 
IgG1, and IgG2 were subsequently incubated and detected using HRP.  Hemaggluniation inhibition 
assays were run using serum incubations with formalin-neutralized PR8 and X31 virus, and were 
detected via visual inspection of hemagglunination patterns.  ELISA was also used to quantify antigen-
specific T-cell response.  Purified splenic T-cells were cultured for 7 days in complete RPMI, then seeded 
into wells and incubated in triplicate with GFP for 48 h.  Anti-IFN-, IL-4, and IL-10 antibodies were then 
used to detect the presence of stimulated cytokine release.  Further proliferation analysis on T-cells was 
also done on similarly cultured T-cells.  Cultured T-cells were trypsinized, centrifuged at 1000 rpm, and 
diluted to 1X106 cells/mL in complete RPMI, then labeled with CFSE (Invitrogen).  2X105 cells were 
seeded into 96-well plates, incubated with 30 L 100 g/mL GFP, and allowed to proliferate at 37 ᵒC for 
4 days.  FACS was used to assess loss of CFSE in proliferating cells.  Additional in vivo inflammation 
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response analysis was done using subdermal injections in BALB/c mice ears (n=4), on which 
histopathology was conducted 30 h post-injection of the OMV samples. 
 
3.2.6: In vitro analysis of immune cell stimulation by EcN OMVs.  Bone marrow-derived macrophages 
were harvested from BALB/c femur bone marrow, column purified, and cultured in complete RPMI for 7 
days.  Following this, they were plated in 6-well plates, incubated with ClyA-GFP(+) OMVs, and assessed 
for phagocytosis-induced fluorescence and IL-12/4/10 expression via FACS analysis.  T-cell activation via 
OMV-pulsed dendritic cells was assessed using DCs incubated for 2 days with OMVs; coculture was 
conducted with CFSE-labeled T-cells in 24-well plates and proliferative analysis was done 7 days 
following initial seeding.  CFSE-labeled B-cells were assessed identically to antigen-restimulated T-cells, 
as described previously.  Knock-out macrophages were acquired as generous gifts from Dr. Cynthia 
Leifer, and were stimulated with OMVs for 3 hours prior to media analysis of TNF-α. 
 
3.2.7: ELISA for serum antibody response.  Polystyrene microtiter 96-well plates (Maxisorp; Nunc 
Nalgene) were coated with GFP (5 µg/ml in carbonate buffer, pH 9.6) and incubated overnight at 4 °C. 
Plates were blocked with 3% BSA in PBS containing 0.05% Tween-20 (PBST). Samples were serially 
diluted 2-fold in blocking buffer in a range of 1:200-1:3,276,800, added to the wells, and incubated for 2 
hours at 37 °C. Plates were washed six times with PBST, and biotinylated goat anti-mouse IgG, IgM 
(Sigma), or monoclonal IgG1 or IgG2 (BD Pharmingen) were added to the wells (1 µg/ml) for 1 hour at 37 
°C. Avidin-HRP (1:1000; Sigma) was then added and incubation continued for 30 min at 37 °C. After six 
additional washes with PBST, 3,3’,5,5’ tetramethylbenzidine substrate (1-Step TMB; Pierce) was added, 
and the enzyme reaction proceeded for 20 min. The reaction was stopped with 2 M H2SO4. The 
absorbance was quantiﬁed in a microplate spectrophotometer at a wavelength of 450 nm. Serum 
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antibody titers were determined by measuring the last dilution that resulted in three standard 
deviations above background.   
 
3.2.8: Splenocyte analyses.  Splenic T-cells were resuspended at a concentration of 2×106 cells/well in 
medium RPMI 1640 (supplemented with FCS and antibiotics), seeded into 96-well plates and incubated 
for 48 h with 5 µg GFP or RPP. Cytokine levels of IFN-γ, IL-4, and IL-10 were measured in the 
supernatants using standard ELISA kits (eBioscience).  Splenocytes were isolated as described above, 
incubated with anti-CD3, anti-CD4, anti-CD8, anti-CD44, and anti-CD25 according to manufacturer 
recommendations (eBioscience), then run on a BD Biosciences LSR II Flow Cytometer.  All analyses were 
done in FlowJo®. 
 
3.3: Results and Discussion 
3.3.1: Assessing OMV stability under physiological conditions relevant to polymeric controlled release 
 It should be noted that OMV controlled release from microspheres is only possible if the OMVs 
themselves can maintain integrity under appropriate conditions related to formulation (induced 
turbulence for emulsion preparation) and in vivo controlled release (pH, temperature) over relevant 
time periods.  Therefore, prior to attempting to formulate microsphere-encapsulated OMV 
preparations, we thoroughly probed the stability of EcN OMVs under a variety of conditions.  The results 
(Fig. 3.2), measured by dynamic light scattering analysis of OMV samples post-incubation, indicate that 
while OMVs are indeed sensitive to prolonged exposure to temperatures above 0 ᵒC and more extreme 
pHs, they are overall stable enough to survive both microparticle formulation and controlled release 
within a vaccinated organism. 
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Figure 3.2: Stability tests done on DLS-analyzed EcN OMV samples.  (A) EcN OMVs in PBS kept 
undisturbed at different temperatures.  (B) EcN OMVs in PBS kept undisturbed at 4 ᵒC with varied pHs.  
(C) EcN OMVs homogenized in 150 mL PBS at variable RPMs.  (A-C)  Percent intact OMVs represent 
analysis of peak intensities from dynamic light scattering measurements, where “intact” OMVs were 
only those comprising a peak that was not associated with degradation or aggregation.  All data 
presented as mean +/- s.d.  All time points representative of independent data (n=3).   
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3.3.2: Initial confirmation of PLGA microparticle encapsulation of model fluorescent EcN OMVs 
 In an initial proof-of-concept study, PLGA microparticles encapsulating EcN OMVs displaying 
ClyA-GFP were prepared in w/o/w emulsion using 50:50 PLGA (MW 24-38 kDa) and 1% poly(vinyl 
alcohol) (MW 17-25 kDa).  The resulting particles demonstrated likely successful OMV encapsulation 
(Fig. 3.3), with selective microsphere sequestration of fluorescence within undried polymeric “droplets” 
visualized under light microscopy.  While this particular initial study did not yield insight into the level of 
intact encapsulation of OMVs, nor their capacity to withhold OMVs meaningfully during controlled 
release, it was a useful check to confirm that OMVs could be successfully packaged under fairly vigorous 
double emulsion conditions. 
3.3.3: In vitro controlled release studies of PLGA microsphere-encapsulated OMVs 
 Two controlled release profiles were created using PLGA microspheres: a zero-order and a step-
wise release.  The general reasoning behind the favorability and greater applicability of such release 
profiles was already discussed in a broader context, but within the narrow focus of applying singular 
release approaches to vaccination, these approaches parallel the two currently accepted methods of 
enhancing immune responses via vaccine administration over time: namely, continuous release or 
periodic re-administration.  PLGA microparticles prepared in high surfactant conditions were observed 
to have decreased porosity, smaller size, and release in a fashion comparable to the former.  Namely, 
release occurred at a fairly continuous rate over the course of 30 days in vitro (Fig. 3.4).  Importantly, 
this was correlated using electron microscopy to the continued release of intact OMVs from gradually 
degrading PLGA microspheres.  This correlation is non-trivial in a pre-animal model assessment, as the 
assumption that OMVs would remain intact during release, though supported by the data in 3.3.2, 
required validation prior to further testing.  Specifically, vesicles are not extremely stable 
bionanoparticles, and as a result some degradation is expected under controlled release conditions.  
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Figure 3.3: OMVs encapsulated within aqueous core PLGA microparticles.  PLGA microparticles formed 
in a double emulsion with PBS have an aqueous core (A) and minimal autofluorescence (B).  When 
concentrated OMVs laden with surface-displayed GFP (C) are mixed into the PBS for the double 
emulsion, the resulting microparticles (D) appear to successfully encapsulate the OMVs (E).  All images 
taken at 100x immediately after completion of second emulsification in 1% PVA (A-B, D-E).  Fluorescent 
images taken at 475 nm excitation (B,C,E). 
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Figure 3.4: Zero-order controlled release of OMVs from PLGA microspheres.  Microspheres formed 
under high PVA emulsion conditions (10%) resulted in 2-5 µm microparticles that released OMVs via 
zero-order linear mechanisms over a 25-30 day period in PBS at 37 °C.  Release was quantified via BCA 
assay of supernatant samples.  Insets at t = 10, 20, and 30 days show in vivo fluorescence tracking (top-
left), TEM micrographs of supernatant OMVs (top-right), and SEM micrographs of degrading 
microspheres.  Bottom left inset shows mouse positioning. 
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However, the integration of these studies makes it fairly clear that intact OMVs are being retained and 
released at a fairly constant rate from these smaller microspheres.  Also of note is the correlation to 
gradual degradation in vivo as well, where whole-body fluorescent imaging of mice post subcutaneous 
injection with near-infrared dyed microspheres revealed similar degradation rates as observed more 
quantitatively in vivo.   
 While linear release has important implications both to simple enhancement of vaccine 
immunogenicity and more complex combinatorial applications given an expanded library, removing the 
reliance of the OMV platform on boosting doses inspired the further investigation of a “self-boosting” 
controlled release mechanism via further fine-tuning of particle synthesis.  By destabilizing the regularity 
of microsphere formation through a lower surfactant content, the PLGA microspheres could be formed 
in a way that higher observed porosity was harnessed to achieve step-wise release over a prolonged 
period (Fig. 3.5).  While this would be exceptionally challenging to achieve with small molecule delivery, 
the substantially smaller size differential between the hydrodynamic radius of an OMV (nanoscale) and a 
microparticle (microscale) allows for fairly straightforward manipulation of microsphere size and 
heterogeneity of composition to create step-wise release of encapsulated OMVs.  Indeed, we observed 
that larger, composite microspheres (~30 µm in diameter) released OMVs in three roughly equal bursts: 
0-7 days, 18-26 days, and 35-40 days following injection, respectively.  While this is not a perfect mimic 
of the prime/boost regimen tested in Chapter 2, it remains mimetic of fairly standard three-dose 
boosting regimens for a variety of commercially available vaccines and thus was considered a likely 
candidate for testing single-dose self-boosting capacity of microsphere-delivered OMVs.  
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Figure 3.5: Stepwise controlled release of OMVs from PLGA microspheres.  Microspheres formed 
under low PVA emulsion conditions (1%) resulted in multilayer 25-30 µm microparticles that released 
OMVs via multi-boost mechanisms over a 40-60 day period in PBS at 37 °C.  Release was quantified via 
BCA assay of supernatant samples.  Insets at t = 10, 20, and 30 days show in vivo fluorescence tracking 
(top-left), TEM micrographs of supernatant OMVs (top-right), and SEM micrographs of degrading 
microspheres.  Bottom left inset shows mouse positioning. 
  
73 
 
3.3.4: Characterization of in vivo immunological enhancement of EcN OMV vaccine carriers via 
controlled release. 
 As first presented in 2.3.1, humoral and cellular responses to EcN OMVs delivering a model 
antigen of GFP were assayed in a BALB/c mouse model.  High anti-antigen IgG titers were maintained 
relative to free OMV injection (Fig. 3.6), further supporting the observation that OMVs released from 
microsphere encapsulation were intact and functional vaccine carriers.  Intriguingly, both controlled 
release mechanisms resulted in 100-fold to 1000-fold increases in titers above negative control baseline 
substantially faster than the standard prime/boost administration of EcN OMVs, which is consistent with 
expected enhancement.  Of substantial importance was the content of this humoral response as well – 
that is, the distribution of IgG2a vs. IgG1 titers within the total IgG population were once again indicative 
of TH1 bias (Fig. 3.7).  This demonstrates that not only are the OMVs released in this fashion still 
immunogenic, they retain the unique immunogenicity of the EcN OMVs.  Cellular responses were also 
observed to be consistent with previously assayed EcN OMV responses: IFN-γ secretion post antigen 
restimulation in vitro substantially outpaced IL-4 secretion, again indicating a TH1-bias (Fig. 3.8).  Of 
particular interest, however, was the resulting IL-10 secretion.  The gradual release of the EcN OMVs 
apparently caused an increase IL-10-secreting T-cells, which could be indicative of continual exposure to 
EcN OMVs leading to a more suppressive response than observed in previous administrations of OMVs.   
 To further explore a differential effect of continuous vs. multi-burst exposure to the EcN OMVs, 
we used flow cytometry to analyze splenic populations of T-cells in vaccinated mice (Fig. 3.9).  
Specifically, we looked at enhancement of antigen-responsive populations of isolated helper, cytotoxic, 
regulatory, and memory T-cells, respectively.  For the former two, we observed a statistically significant 
shift in effector T-cell population towards cytotoxic T-cells in the multi-boost administration versus a 
shift toward helper T-cells in the continuous release administration, which may be indicative of the   
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Figure 3.6: Controlled release of OMVs via PLGA microspheres results in rapid protective levels of 
humoral immunity without additional boost.  BALB/b mice (n=5, all groups) were injected with 100 µL 
of purified model antigen GFP, aluminum hydroxide gel (alum) + GFP, and EcN OMVs displaying GFP 
twice over a course of 8 weeks; zero-order and multi-boost (MB) microparticles were injected once 
subcutaneously at t = 0 weeks.  Given the terminal anti-GFP titer of 1000 for the negative control (GFP 
only), protective humoral immunity correlated to elevated titers was achieved at 100000.  Titers were 
assayed via ELISA.  All data given as mean +/- SD. 
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Figure 3.7: Controlled release of PLGA microspheres retains TH1-biased IgG2a:IgG1 titer ratios of free 
OMV prime/boost injections.   Titers were assayed via ELISA from terminal (t = 8 weeks) submandibular 
bleeds of vaccinated BALB/c mice (n=5, all groups).  *P<0.05, as determined by Tukey’s post-hoc test.  
All data given as mean + SD. 
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Figure 3.8: EcN OMV vaccine retains robust, TH1-biased cellular response in mouse model.  (A-C) 
Cytokine secretion levels from cultured, GFP-restimulated spleen-derived T-cells harvested from end-
point subjects.  Alum = Alhydrogel®.  *P<0.05, **P<0.001 determined by Tukey’s HSD post-hoc test.  All 
values are given as mean + SD. 
  
77 
 
 
 
 
Figure 3.9: Protection conferred by EcN OMV carrier vaccination resulted in splenic T-cell population 
shifts.  (A-C) Flow cytometry data of isolated primary splenocytes (n=5, all groups), normalized to the 
highest value in the data set, on pooled splenic T-cells isolated from mice in c, probing for CD4/CD8 T-
cells (A), regulatory T-cells (B), and memory T-cells (C).  *P<0.05, **P<0.001 determined by Tukey’s HSD 
post-hoc test.  All values are given as mean + SD. 
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former being better suited to applications targeting vaccination against intracellular pathogens.  
Assessment of regulatory T-cells further supported the previous observation that the continuous release 
of EcN OMVs by the smaller microspheres might be enhancing regulatory immunity.  While this might be 
detrimental in certain classical vaccine applications, it opens doors to applications of EcN OMVs as 
immunotherapeutic vaccination for a variety of immunodysfunctions, which will be further explored in 
Chapter 5.  Finally, an important motivation behind testing controlled release applications to OMV 
vaccination was the ability to enhance immunological memory.  The multi-boost regimen in particular 
significantly enhanced antigen restimulation response in memory T-cells, indicating that controlled 
release spectrums (particularly ones that incorporate multiple boosts with periodic levels of slow 
release) can enhance OMV vaccination efficacy in ways primarily reserved for actively pathogenic 
vaccine formulations (such as attenuated viruses). 
 
3.4: Conclusions 
 PLGA microspheres can be readily engineered to enhance the pathogen-mimetic capacity of EcN 
OMV PLP vaccine carriers, with both linear and “self-boosting” release profiles enhancing 
immunogenicity without compromising the capacity of an OMV as a nanoparticulate antigen delivery 
vector.  Moreover, the specific release profile itself might present a new avenue for control over OMV 
immunostimulation.  Specifically, discrepancies in cellular immunity discovered in BALB/c vaccination 
studies indicate that EcN OMVs can benefit from enhanced cellular memory and regulatory responses 
simply by varying the release profile of the encapsulating microsphere, broadening EcN OMV 
applicability as a vaccine carrier for both traditional and non-traditional vaccination applications. 
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CHAPTER 4 
ADAPTATION OF THE ECN OMW VACCINE PLATFORM FOR CREATION OF AN INFLUENZA VACCINE 
CAPABLE OF CROSS-STRAIN PROTECTION 
4.1 Introduction 
 Our interest in the OMVs as recombinant subunit antigen carriers extends beyond use simply for 
other bacterial pathogens.  As proteins from eukaryotes can easily be expressed in a structurally and 
even functionally relevant fashion within bacteria, given appropriate codon optimization/harmonization 
and assuming proper glycosylation is not entirely essential, they can just as easily be incorporated into 
our OMV vaccine carrier platform.  Moreover, as the robust, TH1-biased antigen-specific immunity 
demonstrated by the EcN OMVs in Section 3.1 has important implications for vaccines against any 
intracellular pathogen4,22,77 – bacterial, viral, or eukaryotic – it behooves us to investigate its applicability 
to a model, non-bacterial pathogen.    In this study, we chose H1N1 influenza virus for several reasons.  
First and foremost, influenza is a very well-studied pathogen with a wide market for annual vaccination 
with room for improvement over the current state-of-the-art in terms of ready adaptability to seasonal 
variances in flu strain dominance78.  Second, a vaccine that can achieve cross-protection between 
influenza strains with a single formulation is in high demand, and the fact that our platform combines 
TH1-bias with the potential for total antigen epitopal space presentation (via functionally folded antigen 
surface display) gives it a good chance for achieving some amount of multi-strain protection.  Finally, 
there is a simple in vitro assay for probing the efficacy of anti-hemagglutinin (a key influenza antigen and 
an obvious selection for our vaccine) antibodies by way of a red blood cell hemagglutination-inhibition79.  
This gives us the ability to challenge the functional efficacy of our EcN OMV-stimulated immunity in the 
same BALB/c model used previously without having to fully invest in an actual pathogen challenge 
model to get a sense of more than just antigen-specific immune response stimulation. 
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 Influenza virus, the most common viruses of the Orthomyxovirus family, have been a focus of 
global health and vaccine development in particular for decades, both in the Western world and in the 
developing world.  The virus is transmitted mucosally via contact with surface or aerosolized particles, 
and while not particularly stable, is particularly infectious nonetheless.  Globally, influenza infection is 
characterized both by seasonal epidemics and infrequent pandemics, both of which pose unique 
challenges to vaccine design.  The former is governed by yearly selection of dominant strains of the 
virus, which are characterized by the isoforms of its dominant antigens hemagglutinin and 
neuraminidase, while the latter is primarily driven by the evolution of new infectious strains that often 
occur when viral mutations result in animal influenza strains becoming infectious to humans.  For the 
former, modern vaccines struggle with the mutagenicity of hemagglutinin and neuraminidase – 
specifically, vaccines traditionally have to be made to one form of each (i.e. H5N1, or avian flu) without 
being able to provide ample protection for other forms (i.e. H1N1, or swine flu).  The latter is primarily 
crippled by the response time of current vaccine production technology, which is overly dependent on 
production methods that are dependent on inefficient incubation in hen eggs or recombinantly mutated 
virus production in mammalian cell culture.  While an effective OMV vaccine might be seen by default to 
address the production complication – that is, bacterial production wherein the primary variable is 
simple transformation with an updated plasmid containing isolated antigens – the complication of strain 
diversity due to antigen mutagenicity is less simple.  In general, the field focuses primarily on two 
potential solutions to this challenge: either the identification and vaccination of a non-mutagenic, 
universal antigen that is generally overlooked by the immune system when combating influenza, or 
vaccination using hemagglutinin and/or neuraminidase antigen subunits that results in cross-protection 
between influenza mutants due to presentation of conserved epitopes. 
 In this study, we present a novel approach to inducing cross-strain protection against influenza 
by vaccinating against a hemagglutinin subunit in a pathogen-mimetic fashion utilizing surface 
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presentation of antigen on the EcN OMV carrier.  Specifically, an engineered hemagglutinin subunit from 
an emergent H1N1 strain was incorportated into an EcN OMV vaccine and tested in BALB/c mice for 
development of protective humoral and cellular immunity.  Following demonstration of substantial TH1-
bias to a viral antigen, which is not typical of bacterially-derived recombinant vaccine system, we 
additionally assayed for cross-strain protection against mouse-adapted H3N2 virus.  We found a 
significant enhancement of cross-strain neutralization in our platform relative to standardly adjuvanted 
recombinant vaccination, which is a promising start to further experimentation to quantify the capacity 
of OMV vaccines not just as a replacement technology for current influenza vaccines, but more 
importantly as a recombinant vaccine formulation capable of protecting against more than one strain of 
influenza at a time. 
 
4.2: Materials and Methods 
4.2.1: Preparation of OMVs.  OMVs were purified in accordance with a previously established procedure 
(38) – please see Section 2.2.  Briefly, plasmid pBAD-ClyA-H1HA-His, containing an arabinose promoter, 
was transformed into E. coli Nissle 1917 vesicle-overproducing strain JH1. pBAD-ClyA-H1HA-His 
contained a bacterial codon-harmonized hemagglutinin N-terminal subunit fragment from emergent 
H1N1 influenza strain CA042009, amino acids 50-158. Protein expression was induced at this point by 
addition of L-arabinose to a final concentration of 0.2%.  
4.2.2: Protein Analyses.  Protein concentrations in OMV and purified recombinant protein preparations 
(used as controls in the vaccine study) were quantified by the bicinchoninic-acid assay (BCA Protein 
Assay; Pierce) using BSA as the protein standard.  Fluorescence of GFP in protein and OMV samples was 
measured in a microplate spectrofluorometer (Gemini EM; Molecular Devices) using excitation and 
emission wavelengths of 481 nm and 507 nm, respectively (40).  For SDS/PAGE, samples were prepared 
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in sample-loading buffer containing β-mercaptoethanol and heated at 90 ᵒC for 10 min before 
electrophoresis on 10% polyacrylamide gels.  Proteins were transferred to polyvinylidine difluoride 
membranes for Western blot analysis and probed with monoclonal mouse anti-his tag IgG (Invitrogen; 
1:2000) primary antibody, and horseradish peroxidase conjugated goat anti-mouse IgG (Jackson 
Immunoresearch; 1:10000) secondary antibody.  Membranes were developed by autoradiography with 
ECL detection reagents (GE Healthcare). 
4.2.3: Mouse Immunizations.  Ten groups of ten 8-week old BALB/c mice (Charles River Laboratories) 
each were immunized s.c. with 100 µL of PBS containing purified protein or OMV preparations as 
described.  The ten treatment groups were immunized with, respectively: PBS, 2.5 µg H1N1 HA, 2.5 µg 
ClyA, 2.5 µg ClyA-H1N1 HA fusion, 2.5 µg alum and ClyA-H1N1 HA mixture (Alyhydrogel®, 1.3% aluminum 
hydroxide [mass:volume]), and recombinant fluorescent equivalents of EcJ+ClyA-H1N1 HA, EcJ (empty), 
EcN+ClyA-H1N1 HA, and EcN (empty).  Two doses of vaccine (priming dose and boosting dose) were 
administered 4 weeks apart.  Blood was collected from the mandibular sinus immediately before and 2 
weeks after the first immunization, immediately before the boosting dose, and at 2 and 4 weeks after 
the boosting dose.  Terminal splenectomies were performed on half (n=5) of all ten groups immediately 
before administration of the boosting dose and on the other half (n=5) following the final blood 
collection.  The protocol for the animal studies was approved by the Institutional Animal Care and Use 
Committee at Cornell University (protocol number 2009-0096). 
4.2.4: Assessing OMV vaccine immune response.  Standard microtiter ELISA was performed on 
collected serum samples from vaccinated mice in 96-well plates.  Wells were incubated with purified 
GFP overnight, followed by serial dilution incubation with serum.  Secondary antibodies for IgG, IgM, 
IgG1, and IgG2 were subsequently incubated and detected using HRP.  Hemaggluniation inhibition 
assays were run using serum incubations with formalin-neutralized PR8 and X31 virus, and were 
detected via visual inspection of hemagglunination patterns.  ELISA was also used to quantify antigen-
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specific T-cell response.  Purified splenic T-cells were cultured for 7 days in complete RPMI, then seeded 
into wells and incubated in triplicate with GFP for 48 h.  Anti-IFN-, IL-4, and IL-10 antibodies were then 
used to detect the presence of stimulated cytokine release.  Further proliferation analysis on T-cells was 
also completed on similarly cultured T-cells.  Cultured T-cells were trypsinized, centrifuged at 1000 rpm, 
and diluted to 1X106 cells/mL in complete RPMI, then labeled with CFSE (Invitrogen).  2X105 cells were 
seeded into 96-well plates, incubated with 30 L 100 g/mL GFP, and allowed to proliferate at 37 ᵒC for 
4 days.  FACS was used to assess loss of CFSE in proliferating cells.  Additional in vivo inflammation 
response analysis was done using subdermal injections in BALB/c mice ears (n=4), on which 
histopathology was conducted 30 h post-injection of the OMV samples. 
4.2.5: In vitro analysis of immune cell stimulation by EcN OMVs.  Bone marrow-derived macrophages 
were harvested from BALB/c femur bone marrow, column purified, and cultured in complete RPMI for 7 
days.  Following this, they were plated in 6-well plates, incubated with ClyA-GFP(+) OMVs, and assessed 
for phagocytosis-induced fluorescence and IL-12/4/10 expression via FACS analysis.  T-cell activation via 
OMV-pulsed dendritic cells was assessed using DCs incubated for 2 days with OMVs; coculture was 
conducted with CFSE-labeled T-cells in 24-well plates and proliferative analysis was done 7 days 
following initial seeding.  CFSE-labeled B-cells were assessed identically to antigen-restimulated T-cells, 
as described previously. 
4.2.6: ELISA.  Polystyrene microtiter 96-well plates (Maxisorp; Nunc Nalgene) were coated with GFP (5 
µg/ml in carbonate buffer, pH 9.6) and incubated overnight at 4 °C. Plates were blocked with 3% BSA in 
PBS containing 0.05% Tween-20 (PBST). Samples were serially diluted 2-fold in blocking buffer in a range 
of 1:200–204,800, added to the wells, and incubated for 2 hours at 37 °C. Plates were washed six times 
with PBST, and biotinilated goat anti-mouse IgG, IgM (Sigma), or monoclonal IgG1 or IgG2 (BD 
Pharmingen) were added to the wells (1 µg/ml) for 1 hour at 37 °C. Avidin-horseradish peroxidase 
(1:1000; Sigma) was then added and incubation continued for 30 min at 37 °C. After six additional 
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washes with PBST, 3,3’,5,5’ tetramethylbenzidine substrate (1-Step TMB; Pierce) was added, and the 
enzyme reaction proceeded for 20 min. The reaction was stopped with 2 M H2SO4. The absorbance was 
quantiﬁed in a microplate spectrophotometer at a wavelength of 450 nm. Serum antibody titers were 
determined by measuring the last dilution that resulted in three standard deviations above background.  
For the determination of cytokines, cells were resuspended at a concentration of 2×106 cells/well in 
medium RPMI 1640 (supplemented with FCS and antibiotics), seeded into 96-well plates and incubated 
for 48 h with 5 µg GFP. Cytokine levels were measured in the supernatants by using standard ELISA kits 
(eBioscience). 
4.2.7: Hemagglutination Inhibition Assays.  Samples of A/PR8/34 and X31 influenza virus were 
inactivated in 0.02% formalin for 18h at 37°C, and then dialyzed against PBS at room temperature 
overnight.  Each virus sample was titered for stock hemagglutination units (HAs) as described elsewhere 
(42) using serial two-fold dilutions of virus into freshly-drawn 1% MRBCs in PBS.  Subsequently, serial 
two-fold dilutions of serum from appropriately vaccinated mice were incubated as described elsewhere 
(42) with 4 HA diluted virus samples and then exposed to 1% MRBCs in PBS.  Both assays were read 
using the teardrop method to determine the cut-off between hemagglutination and hemagglutination 
absence/inhibition. 
4.2.8: T-cell Activation Analyses.  T-cell activation by stimulated DCs was assayed as described 
previously (46,47).  Briefly, 96-well plates were incubated overnight with 10 µg/mL anti-mouse CD3 
(clone 145-2C11; BD Biosciences) at 4 ᵒC, after which plates were washed 3 times with complete RPMI.  T 
cells were then labeled with CFSE as described and seeded into wells from at 2X105 cell/well.  T-cells 
were co-incubated with 4X104 cell/well DCs, 5 µg/mL anti-mouse CD28 (clone 37.51, Biolegend), and 1-
100 µg/mL EcJ or EcN OMVs.  Samples prepared for flow cytometry analysis incubated for 48 h at 37 ᵒC, 
incubated for 4-6 h with 25 ng/mL PMA, 1 µg/mL ionomycin, and 10 µg/mL brefeldin A, and then were 
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collected and stained with IFN-γ and IL-10 (eBiosciences).  Samples prepared for ELISA analysis of culture 
supernatants were also incubated for 48h at 37 ᵒC.  Samples prepared for proliferation analysis were 
incubated at 37 ᵒC for 7 days, then trypsinized and analyzed by flow cytometry for loss of CFSE staining. 
 
 
4.3: Results and Discussion 
 Using a ClyA-H1N1 hemagglutinin fusion (expressed from a codon-optimized sequence derived 
from CA0409HA), we engineered EcN OMVs that surface displayed hemagglutinin as a recombinant 
antigen.  A similar BABL/c mouse trial and subsequent humoral and cellular immune analysis were used 
as in Chapter 2, and the results were as expected: despite being a non-bacterial protein, humoral (Fig. 
4.1) and cellular (Fig. 4.2) immunity specific to H1N1 hemagglutinin (derived from A/PR8/34 H1N1 viral 
capsids) was similar to that found previously.  More impressive, however, were the results of the 
hemagglutination-inhibiton (HI) assay (Fig. 4.3).  First, HI antibody titers against formalin-inactivated 
A/PR8/34 were comparable between serum from BALB/c mice vaccinated with H1N1 HA(+) EcN OMVs 
and an alum control, demonstrating that the OMV platform not only generates antigen-specific humoral 
immunostimulation comparable to traditional adjuvants, but additionally creates functional humoral 
immunity in the form of sufficient opsonizing/neutralizing antibody populations.  The more interesting 
observation, however, came when we probed the same sera for cross-protection against H3N2 influenza 
hemagglutination (using H3N2 strain X31).  While the alum control’s HI titer plummeted, as expected, 
the EcN OMVs’ HI titer remained fairly high and well above statistically significant functional range 
compared to the PBS negative control.  While not conclusive, this strongly suggests EcN OMVs have the  
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Figure 4.1: EcN OMV carriers generate strong anti-H1N1 HA humoral immunity.  (A-C) Terminal data 
points from BALB/c mice vaccinated and boosted once (or not boosted, as noted) with antigen-
normalized (or protein normalized, as appropriate) with EcN OMVs and controls (n=5).  (A-B) Class-
specific anti-H1N1 HA antibody serum titers.  (C) Ratio of serum titers of IgG1 to IgG2.  (A-C) Alum = 
Alhydrogel®.  *P<0.005, **P<0.05 determined by Tukey’s HSD post-hoc test.  All values are given as 
mean + s.d.   
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Figure 4.2: EcN OMV carriers generate strong anti-H1N1 HA cellular immunity.  (A-C) Terminal data 
points from BALB/c mice vaccinated and boosted once (or not boosted, as noted) with antigen-
normalized (or protein normalized, as appropriate) with EcN OMVs and controls (n=5).  (A) Proliferation 
index of antigen-restimulated spleen-derived T-cells harvested from end-point subjects, measured via 
CFSE stain.  (B-C) Cytokine secretion levels from cultured, antigen-restimulated spleen-derived T-cells 
harvested from end-point subjects.   (A-C) Alum = Alhydrogel®.  *P<0.005, **P<0.05 determined by 
Tukey’s HSD post-hoc test.  All values are given as mean + s.d.   
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Figure 4.3: Cross-strain protection is enhanced by recombinant hemagglutinin delivery via EcN OMVs.  
Data was gathered from serum antibodies collected exclusively from terminal cardiac punctures 
assessed via hemagglutinin inhibition assays run on inactivated viral capsids.  Alum = Alhydrogel®. 
**P<0.05 determined by Tukey’s HSD post-hoc test.  All values are given as mean + s.d.   
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capacity as antigen carriers to facilitate influenza cross-strain protection, something vaccinologists have 
struggled to achieve with classical adjuvants.   
Considering the fact that this level of cross-strain reactivity is comparable to the discrepancy78 
found between individuals who have actually been infected with H1N1 (and have cross-strain 
immunity), and those who have only been vaccinated against H1N1 (and do not have cross-strain 
immunity), our findings also lend additional insight into the function of our platform as a PLP.  In 2.3.2, 
we noted a strong capacity for T-cell independent B-cell activation via our EcN OMVs, indicating they 
had the potential for presenting surface displayed antigens to B-cell receptors in an immunostimulatory 
fashion.  The presence of enriched quantities of PAMP-rich biomolecules with an expanded range of TLR 
targets further supports a capacity for surface antigen presentation in tandem with self-adjuvanting co-
stimulation.  We also found in 2.3.4 that surface presentation in particular appeared to be important for 
EcN OMV antigen delivery, meaning it was somehow inherently involved in the stimulated antigen-
specific response.  Coupled with our observation of ClyA-GFP fusions resulting in surface displayed, 
functionally folded GFP34, one could hypothesize that this B-cell presentation has the fairly unique 
capacity among non-whole pathogen vaccine formulation to present a full range of antigen linear and 
conformational epitopes in a relevantly immunogenic fashion.  This hypothesis is well-supported by the 
results of this HI assay.  While sequence mutations between strains result in modified linear epitopes 
and thus non-convergent immunity (should reactivity to such epitopes dominate the antibody 
population), divergent strain hemagglutinins are still functionally similar and thus often contain similar 
conformational epitopes.  The ability to present an H1N1 HA to the immune system in a way that 
preserves its folded structure, as an intact virus obviously would and we hypothesize our EcN OMVs can, 
could therefore result in an expanded antibody population that targets conformational epitopes and can 
result in cross-protection.  As this hypothesis correlates well with our data, we can at least tentatively 
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conclude that our EcN OMV is indeed functioning as a true PLP: delivering its antigen in a way that is 
functionally mimetic of an actual viral pathogen. 
 
4.4: Conclusions 
 In this report, two key findings drive a continued interest in the adaptation of the EcN OMV 
platform for use as a recombinant vaccine carrier for vaccination against viral pathogens.  First, 
vaccination in a mouse model demonstrated the stimulation of protective immunity against a 
bacterially-expressed recombinant subunit antigen of a viral protein.  Second, the humoral response was 
quantified as being not only inhibitive on the level of a standardly adjuvanted control, but more 
importantly that this inhibition transferred to another strain containing a different form of 
hemagglutinin.  The latter result bears the most attention in further testing, as it may be evidence of the 
realization an elusive promise of PLP vaccines, and therefore requires more rigorous challenge in an 
infectious protection mouse model.  Finally, the observation that a lack of boosting resulted in a lack of 
protection serves as important inspiration for adaptation of microsphere controlled release from 
Chapter 3 as a general facet of OMV vaccination, as for a new influenza vaccine to be competitive in the 
current market single-dose vaccination is likely a necessary feature.  Regardless, the results presented 
herein are encouraging and demonstrate the robust applicability of EcN OMVs as vaccine carrier PLPs to 
non-bacterial antigen targets. 
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CHAPTER 5 
ADAPTATION OF THE ECN OMW VACCINE PLATFORM FOR THE TREATMENT OF PEANUT ALLERGIES: 
GENERATION OF A PROPHYLACTIC PEANUT ALLERGY VACCINE AND CONTROLLED RELEASE OMV-
MEDIATED IMMUNOTHERAPY 
5.1 Introduction 
 While pathogen vaccine targets are certainly the most obvious application of a recombinant 
subunit antigen carrier platform such as the EcN OMV, they are not the only ones.  Indeed, setting aside 
the classic medical definition of a vaccine as a prophylactic immunological treatment of pathogenic 
organism infection, at its core a vaccine delivery platform is much more simply a targeted 
immunomodulator.  That is, its purpose is to alter the immune response in a favorable way to an 
exogenous moiety of interest.  This consideration has certainly not been lost on the field of vaccine 
engineering.  Vaccinologists, and even some more specialized molecular engineers working on PLPs, 
have pursued vaccines against everything from cancer24,80, to Alzheimer’s disease, to nicotine8,21.  While 
such uses of vaccines are not currently on the market (though a vaccine for leukemia therapy81 could 
become the first FDA approved example shortly), their development speaks to a broader potential of 
vaccine engineering – using the immune system to alter non-pathogenic disease via relevant molecular 
targeting.  While we are indeed quite interested in the prospect of a cancer vaccine (see 4.3.2), our first 
target for non-pathogen vaccination is allergy.  This target represents an understandable middle ground: 
allergy is a non-pathogenic disease that the immune system is obviously highly involved with on a 
fundamental level, and immunomodulation therapy for the treatment of allergy is common. 
 Our model for allergy vaccination will be allergies to Arachis hypogaea, or peanuts.  Food 
allergies are common among children three years and younger, with 6-8% of children having 
hypersenstive allergic reactions to products such as cow milk, eggs, and peanuts82. While 80-85% of 
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children eventually outgrow these allergies, approximately 1.5 million people in the US remain 
anaphylactically hypersensitive to peanut allergens throughout adulthood82,83. Current forms of 
management and rescue from severe peanut-induced anaphylaxis are limited83,84. While sensitization 
and other immunotherapies have been used to treat a variety of food allergies, exposure to even minute 
amounts of peanut allergen is prohibitively risky for hypersensitive individuals. This situation has 
prompted investigation into prophylactic vaccination as a potential means to prevent hypersensitive 
allergy altogether85. With such an approach, the immune system’s propensity for quantal memory 
responses is harnessed to artificially simulate the TH1-polarizing requirements of the ‘hygiene 
hypothesis’86,87. While promising in theory, this approach requires strongly biased cellular immunity 
against the allergen beyond the capacity of currently available adjuvants77. 
 The systematic modulation of immunity required for protection against type I hypersensitivity 
allergy, as found in cases of peanut allergy, is challenging to achieve using conventional adjuvants1,2.  
However, building on the success of the EcN OMV vaccine carrier reported in Section 2, there is ample 
evidence to hypothesize that the immunomodulation harnessed via this vaccine delivery approach could 
be beneficially applied to this medical challenge.  Herein, we report the success of two adaptations of 
the EcN OMV system’s PLP properties as a therapeutic prevention of symptoms related to 
hypersensitivity allergy in a mouse model for food allergy-triggered anaphylaxis.  First, we demonstrate 
the efficacy of a prophylactic formulation using the standard prime/boost administration of EcN OMVs 
displaying Arah2 peanut allergen subunits, with vaccination occurring prior to sensitization.  This 
administration resulted in 100% protection against lethal anaphylactic challenge and a protection 
against all detrimental symptoms in 60% of mice during challenge.  Second, we report the adaptation of 
the EcN OMV’s PLP capacity to a controlled release therapy using low-dose administration through the 
zero-order release scheme discussed in Chapter 3.  The goal with this adaptation is to use the potent 
self-adjuvancy of the EcN OMV platform (combined with its capacity for immunity-direction at low 
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doses, as described in 2.3.4) to serve as a replacement for traditional immunotherapy, which suffers 
from low patient compliance and efficacy concerns.  This unconventional use of PLPs was also 
successful, resulting in protection from anaphylaxis in line with a standard weekly sublingual 
immunotherapy from a single injection of microparticles. 
 
5.2: Materials and Methods 
5.2.1: Mouse Immunizations. BALB/c mice (Charles River Laboratories) were primed and boosted s.c. 
with PBS containing purified protein or OMV preparations as described. The treatment groups were 
immunized with 100 µL of, respectively: PBS, raw peanut protein (RPP), ClyA, RPP and ClyA mixture, 
ClyA-RPP fusion, alum and ClyA-RPP mixture, and recombinant equivalents of EcJ OMVs + ClyA-RPP, EcJ 
OMVs (with no recombinant antigen, or “empty”), EcN OMVs  + ClyA-Arah2, and EcN OMVs (empty). 
Blood was collected from the mandibular sinus and terminal splenectomies were performed.  
 
5.2.2: Adaptive Immunity Analysis. ELISAs were conducted using 96-well plates that were coated with 
RPP, blocked, coated with serum samples, and incubated/washed prior to reading as reported 
previously12. In the proliferation and cytokine assays, cultured T-cells were trypsinized, centrifuged, and 
diluted in complete RPMI, then labeled with CFSE (Invitrogen).  The cells were seeded into 96-well 
plates, incubated with RPP, and allowed to proliferate at 37 °C for 4 days.  FACS was used to assess loss 
of CFSE in proliferating cells, while standard ELISA kits (eBioscience) were used to assess cytokines. T-cell 
activation by stimulated DCs was assayed similarly, allowing 2 days prior to DC coculture.  
 
5.2.3: Peanut protein sensitization and peanut allergy challenge of mice with corresponding analysis 
of serum and T-cells. Mice were sensitized over a period of 3 weeks following the 8-week vaccination 
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protocol described above.  All mice went through 3 rounds of sensitization (once per week).  Each round 
involved oral administration of 1 mg RPP mixed with 10 μg cholera toxin per mouse via gavage, followed 
by intraperitoneal injection of 0.5 μg RPP mixed with Alhydrogel® on the next day. Mice were challenged 
with RPP following the completion of sensitization.  Anaphylaxis was scored over a 30 minute interval 
immediately following the challenge, using a scoring system between 0 and 5, 0 having no observable 
reaction and 5 being death.  
Histamine ELISAs are performed as described above. Splenocytes were isolated as described above, 
incubated with anti-CD3, anti-CD4, anti-CD8, anti-CD44, and anti-CD25 according to manufacturer 
recommendations (eBioscience), then run on a BD Biosciences LSR II Flow Cytometer.  All analyses were 
done in FlowJo®. 
 
5.2.4: OMV encapsulation in PLGA microspheres.  OMVs were emulsified in a dichloromethane solution 
of poly(lactic-co-glycolic-acid) (PLGA) for 20 seconds using a handheld homogenizer at 18000 rpm (VWR 
Disperser VDI12, Dispersing Tool S12N-5S).  Subsequently, this solution was emulsified in 10% or 1% 
polyvinyl alcohol (PVA) in aqueous solution, generating 2-5 µm and 15-20 µm microspheres respectively.  
Particles were harvested via centrifugation (5000g, 5 min, 4°C) following evaporative stirring in 0.3% 
PVA for 3 hours.  Microspheres were then washed with deionized water and lyophilized following 
resuspension in an aqueous glucose buffer. 
 
5.2.5: Sublingual immunotherapy dosing.  100 µL of RPP (10 µg – 1 mg) mixed with 50 U of vitamin D3 
and 500 µg dexamethasone (Sigma Aldrich) was administered orally under the tongue of sensitized 
BALB/c mice for 12 weeks leading up to challenge.  Dosing was given on a weekly ramp of RPP 
administration as follows: 10, 15, 30, 150, 300, 400, 500 µg.  Mice were observed for 20 minutes 
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following this administration to ensure a lack of reaction, with continued observation occurring for the 
next 24 hours. 
5.2.6: ELISA for Serum Antibody Response.  Polystyrene microtiter 96-well plates (Maxisorp; Nunc 
Nalgene) were coated with RPP (5 µg/ml in carbonate buffer, pH 9.6) and incubated overnight at 4 °C. 
Plates were blocked with 3% BSA in PBS containing 0.05% Tween-20 (PBST). Samples were serially 
diluted 2-fold in blocking buffer in a range of 1:200-1:3,276,800, added to the wells, and incubated for 2 
hours at 37 °C. Plates were washed six times with PBST, and biotinylated goat anti-mouse IgG, IgM 
(Sigma), or monoclonal IgG1 or IgG2 (BD Pharmingen) were added to the wells (1 µg/ml) for 1 hour at 37 
°C. Avidin-HRP (1:1000; Sigma) was then added and incubation continued for 30 min at 37 °C. After six 
additional washes with PBST, 3,3’,5,5’ tetramethylbenzidine substrate (1-Step TMB; Pierce) was added, 
and the enzyme reaction proceeded for 20 min. The reaction was stopped with 2 M H2SO4. The 
absorbance was quantiﬁed in a microplate spectrophotometer at a wavelength of 450 nm. Serum 
antibody titers were determined by measuring the last dilution that resulted in three standard 
deviations above background.   
 
5.2.7: Cytokine Secretion Analyses.  Splenic T-cells were resuspended at a concentration of 2×106 
cells/well in medium RPMI 1640 (supplemented with FCS and antibiotics), seeded into 96-well plates 
and incubated for 48 h with 5 µg GFP or RPP. Cytokine levels of IFN-γ, IL-4, and IL-10 were measured in 
the supernatants using standard ELISA kits (eBioscience).   
 
5.2.8: Peanut Allergy Challenge.  Mice were challenged with 200 ug RPP following the completion of the 
3 rounds of sensitization.  Anaphylaxis was scored over a 30 minute interval immediately following the 
challenge, using the following scoring system: 0, no observable reaction; 1, mild general agitation, 
scratching at nose and/or head; 2, intermittent lethargy, elevated respiratory rate, and/or ocular 
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redness; 3, visibly labored respiration, decreased response to stimuli, and/or consistent lethargy; 4, 
insufficient respiration, lack of response to stimuli, and/or convulsions; 5, death.  Mice that entered a 4 
or higher for longer than 10 minutes, and any mice that remained at a 3 or higher after 30 minutes, 
were euthanized according to recommendation from the IACUC. 
 
5.3: Results 
 
5.3.1: EcN OMVs direct TH1-biased immunity against Arah2 allergens in BALB/c mice 
 We began as in Chapter 2 with an assay of antigen-specific immunogenicity in BALB/c mice.  This 
was an essential first step due to the nature of the antigen subunit target, which was selected to be the 
peanut protein Arah288.  Arah2, being a eukaryotic plant protein, posed the risk of not being sufficiently 
expressible in bacteria, or, if expressible, ran the risk of not folding in a fashion appropriate to generate 
meaningful anti-antigen specific immunity.  To help ensure success, we began by codon-harmonizing the 
Arah2 sequence through Invitrogen’s GeneArt® GeneOptimizer® algorithm.  The resulting sequence was 
expressed as a ClyA-fusion and vaccinated as done previously against a positive control of alum and raw 
peanut protein (RPP).  The immune response was then assayed as before against RPP, not purified 
recombinant Arah2, to ensure the desired retention of anti-antigen immunity.  EcN OMV-induced 
humoral (Fig. 5.1) and cellular (Fig. 5.2) immunity was, as expected, equivalent to initial observations 
using GFP as a model antigen in 2.3.1, demonstrating that at least in certain cases codon harmonization 
is sufficient to preserve eukaryotic protein antigenicity when delivered by the EcN OMV, though further 
studies would be required to make conclusive statements concerning whether or not this explicitly 
stems from retained tertiary antigen structure.  Additionally, the Arah2-specific immune response in this 
study was clearly sufficient to warrant a more meaningful trial in a murine hypersensitivity model. 
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Figure 5.1: EcN OMV carriers generate strong anti-Arah2 humoral immunity.  (A-C) Terminal data 
points from BALB/c mice vaccinated and boosted once with antigen-normalized (or protein normalized, 
as appropriate) with EcN OMVs and controls (n=5).  (A-B) Class-specific anti-Arah2 antibody serum titers.  
(C) Ratio of serum titers of IgG1 to IgG2.  (A-C) Alum = Alhydrogel®.  *P<0.005, **P<0.05 determined by 
Tukey’s HSD post-hoc test.  All values are given as mean + s.d.   
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Figure 5.2: EcN OMV carriers generate strong anti-Arah2 cellular immunity.  (A-C) Terminal data points 
from BALB/c mice vaccinated and boosted once with antigen-normalized (or protein normalized, as 
appropriate) with EcN OMVs and controls (n=5).  (A) Proliferation index of antigen-restimulated spleen-
derived T-cells harvested from end-point subjects, measured via CFSE stain.  (B-C) Cytokine secretion 
levels from cultured, antigen-restimulated spleen-derived T-cells harvested from end-point subjects.  (A-
C) Alum = Alhydrogel®.  *P<0.005, **P<0.05 determined by Tukey’s HSD post-hoc test.  All values are 
given as mean + s.d.   
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5.3.2: Prophylactic vaccination with EcN OMVs protects against anaphylactic challenge in sensitized 
BALB/c mice 
With the mechanistic interface between EcN OMVs and innate and adaptive immunity thoroughly 
characterized in Chapter 2, and with the data presented in 5.3.1 strongly indicating a preservation of 
this mechanism for delivered Arah2 antigenic subunits, we focused on their potential to protect against 
induction of peanut allergen hypersensitivity. Mice were vaccinated with EcN OMVs carrying the peanut 
allergen Arah2 prior to sensitization and challenge (Fig. 5.3), and, following subsequent sensitization, 
reduced serum titers of IgA and IgE reactive to raw peanut protein (RPP) revealed modulation of the 
immune response by the EcN OMVs indicative of protection, unlike the negligible effects of a control 
TH2-biasing alum adjuvanted vaccine (Fig. 5.4). Challenge with a large RPP dose confirmed protection by 
the EcN OMV vaccine, leading to 100% protection for challenged mice rather than terminal anaphylaxis 
(Fig. 5.5).  
To explore the link between EcN OMV antigen delivery and protective tolerance, we further probed 
the specific immune response to sensitization and challenge. Competitive histamine ELISA on post-
challenge serum samples confirmed the prevention of cytokine-driven anaphylaxis via vaccine-induced 
immunomodulation that successfully neutralized the effects of sensitization (Fig. 5.6). Analysis of splenic 
T-cells following sensitization and challenge helped to clarify the cellular component of this response. 
While both OMV-delivered and alum-adjuvanted vaccinations resulted in an engagement of some 
activated and regulatory cellular immunity post-sensitization (Fig. 5.7a,Fig. 5.8a-d), EcN OMV antigen 
delivery more successfully controlled an overactive cellular response in the form of decreased active 
CD4+ and CD8+ effector T-cells (Fig. 7b, Fig. 8e-l), likely facilitated by stronger engagement of 
immunological memory3 (Fig. 7c, Fig. 8m-p). This finding could be a crucial discrepancy, as it highlights 
the fact that simply engaging a cellular response does not necessarily prevent type I hypersensitivity, 
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Figure 5.3: Schedule for prophylactic EcN OMV vaccine trial – vaccination, sensitization, and challenge.  
Vaccination, sensitization, and challenge schedule for mice used in the experiment. Abbreviations: RPP = 
raw peanut protein, CT = cholera toxin, sc = subcutaneous injection, o = oral administration, ip = 
intraperitoneal injection. 
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Figure 5.4: EcN OMV vaccination results in significant decrease in humoral mediators of allergy 
following attempted sensitization.  Serum titers of anti-RPP IgA and IgE following sensitization show 
reduced allergy induction in EcN OMV-vaccinated mice. *P<0.05, as determined by Tukey’s post-hoc 
test.  All values given are mean + SD. 
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Figure 5.5: EcN OMV carriers protect against peanut allergy induction, anaphylaxis.  Anaphylactic 
responses (scored 1-5) of vaccinated mice (n=5, all groups) post-sensitization and challenge with raw 
peanut protein (RPP). All mice with a score above 3 were euthanized after 30 min, while all other mice 
fully recovered, including 100% protected by the EcN OMV vaccine. *P<0.05, as determined by Tukey’s 
post-hoc test.  All values given are mean +/- SD. 
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Figure 5.6: Serum histamine levels immediately post-challenge were significantly less elevated in mice 
protected by prophylactic EcN OMV carrier vaccination.  *P<0.05, as determined by Tukey’s post-hoc 
test.  All values given are mean + SD. 
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Figure 5.7: Protection conferred by EcN OMV carrier vaccination resulted in splenic T-cell population 
shifts.  (A-C) Flow cytometry data of isolated primary splenocytes, normalized to the highest value in the 
data set, on pooled splenic T-cells isolated from mice in c, probing for regulatory T-cells (A), CD4/CD8 T-
cells (B), and memory T-cells (C).   
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Figure 5.8: Flow cytometry analysis of splenic T-cells from sensitized mice, expanded data 
set.  CD4
+ 
T-cells (a-d, m-p) or non-purified splenocytes (e-l) isolated from sensitized mice 
were tagged with fluorescent antibodies for CD25 (a-d), CD4 (e-h), CD8 (i-l), or CD44 (m-p) 
and analyzed using flow cytometry.  Cell sources: PBS (a,e,i,m); PBS, sensitized (b,f,j,n), 
Alum+RPP, sensitized (c,g,k,o); and EcN(Arah2), sensitized (d,h,l,p). Samples represent pooled 
splenocyte populations (n=5).   
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but more sophisticated cellular analysis will likely be required to fully understand the underlying 
mechanism of protection.  
 
5.3.3: Immunotherapy for peanut allergy possible via controlled release of EcN OMV vaccine carriers 
 Following successful demonstration of protective effects generated by EcN OMV vaccine PLPs 
administered prophylactically prior to sensitization, we next attempted to elucidate the effect the 
vaccine particles might have as immunomodulators if instead of being carriers for the allergens as a 
vaccine, they were instead carriers for the allergens as inducers of a competing immune response.  
Specifically, given how current immunotherapy is hypothesized to work by creating competing 
suppressive immunity by exposure to an allergen in tandem with immunosuppressing compounds, we 
rationalized that we could achieve similar effects with low doses of allergen delivered via EcN OMVs.  
Moreover, since the adjuvancy would be directly tied to the allergens via PLP delivery, we were able to 
take advantage of the microsphere-mediated controlled release described in Chapter 3 to both slow the 
administration even more (thereby preventing side effects from an overexposure to the allergen) while 
not requiring the weekly administration current immunotherapies are limited by.   
 As in 5.3.2, mice were sensitized, this time being treated with OMVs therapeutically rather than 
prophylactically.  Following challenge, we observed encouraging protection by all OMV formulations: 
smaller zero-order release microparticles, larger multi-boost microparticles, and even free OMVs given 
similar to a vaccine (Fig. 5.9).  Specifically, protection was conferred in a similar fashion as the 
dexamethasone-mediated immunotherapy.  Importantly, histopathology of lung and intestinal sections 
revealed that controlled release schemes were capable of eliminating immunologically-mediated side 
effects from simply administering the OMVs in full vaccine doses (Fig. 5.10), which, while required under  
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Figure 5.9: Protection against anaphylactic challenge is conferred by controlled release 
immunotherapy doses of EcN OMVs displaying Arah2 antigen subunits.  Anaphylactic responses 
(scored 1-5) of treated mice (n=5, all groups) post-sensitization and challenge with raw peanut protein 
(RPP). All mice with a score above 3 were euthanized after 30 min, while all other mice fully recovered. 
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Figure 5.10: Lung and intestinal inflammation caused by normal administration of freely injected 
OMVs is prevented by controlled release.  Tissue infiltration of inflammatory immune cells and 
associated tissue damage (scored 0-7) of treated mice (n=3, all groups) post-sensitization and challenge 
with RPP.  
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normal circumstances to induce the necessary immunity, unsurprisingly caused hypersensitivity when 
the mouse was exposed to that much allergen at once in immunostimulating circumstances.   
 Noting the success of the OMV-mediated therapy, we hypothesized two possible mechanisms: 
1) the EcN OMVs had achieved a parallel response in accordance with normal immunotherapy methods 
that had competed with the hypersensitivity response upon anaphylactic challenge, or 2) the EcN OMVs 
had been such potent immunomodulators that they had achieved a quantal shift in immunity to their 
traditional TH1 bias.  In assaying the time-evolution of a humoral response post-treatment, we did 
indeed observe a dramatic response in line with a vaccine-like IgG response from both therapies (Fig. 
5.11), supporting that one of the above hypotheses concerning mechanism of action was likely accurate 
– that is, the observed protection was conferred either by a change in the immune response once the 
elevated allergen-specific immunity had returned to a baseline value, or alternatively by the creation of 
a parallel immune response.  Assaying for TH1 bias in the serum IgG2a vs. IgG1 titers (Fig. 5.12) partially 
ruled out the admittedly less likely hypothesis of a quantal shift in immunity, however, as the overall 
composition of the anti-Arah2 humoral immunity remained essentially unchanged following the surge in 
total IgG titers following any treatment regimen.  Further characterization of this immune response, 
such as via T-cell restimulation assays coupled with flow cytometry, may be beneficial to better 
elucidate just how the competing reaction generated by the EcN OMVs works, and what insights it might 
shed towards further harnessing the probiotic advantage via PLPs. 
5.4: Conclusions 
 EcN OMVs displaying Arah2 antigen subunits were demonstrated to be effective therapies for 
peanut allergy in a mouse model.  Interestingly, application of controlled release microsphere 
encapsulation allowed these OMVs to either be used as a prophylactic vaccine, which relied on a quantal 
establishment of non-hypersensitivity immunity, or as a more standard immunotherapy following  
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Figure 5.11: EcN OMV Immunotherapy results in sharp increase in anti-Arah2 IgG titers following 
administration in sensitized mice.  Serum IgG titers derived from ELISAs run on pre-challenge mice jaw 
bleed samples (n=5, all groups).  
111 
 
 
Figure 5.12: EcN OMV immunotherapy did not succeed in creating a TH1 bias in overwriting 
sensitization hypersensitivity immunity, despite protecting against it.  Serum IgG titers derived from 
ELISAs run on pre-challenge mice jaw bleed samples (n=5, all groups) taken immediately prior to 
anaphylactic challenge.  
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sensitization, which did not seem to rely on TH1 biased immunity to protect against anaphylaxis.  While 
prophylactic vaccination seemed to result in a greater control of symptoms in the mouse model, and 
required less modification to achieve acceptable results in minimizing both injection number and 
associated side effects, the concept of a universal prophylactic vaccine for allergies is still a fairly novel 
and controversial concept.  On the other hand, enhanced immunotherapy modalities for control of 
allergy remains the widely accepted standard of care, and the general improvement of such modalities 
is an important goal of allergy study.  As a result, both adaptations of the EcN OMV platform described 
here are of interest and bear further investigation for clinical development as improved treatment and 
prevention of the growing food allergy epidemic.  
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CHAPTER 6 
CONCLUSIONS AND RECOMMENDATIONS 
 
 Engineering pathogen-like particle (PLP) vaccines can be a complicated science, whether it 
requires building a nanoparticle one component at a time or deriving biomimicry from a complicated 
biomaterial.  But the benefits of using a PLP-guided approach to vaccination have clear advantages.  It 
has been a long-accepted fact in the vaccine engineering community that the molecular and functional 
complexity of intact pathogens, while presenting its own list of complications, can direct the most 
potent immune responses.  The immune system itself, having evolved to develop strong responses to 
aggregations of molecular and cellular interactions with pathogens, clearly benefits from an adjuvanting 
effect that goes beyond chemical disruption of native tissue or the engagement of a single 
immunostimulatory co-receptor per antigen.  As a result, PLP-directed vaccine responses will likely 
continue to be a focus of vaccine engineering for some time.  In this work, we contribute to the 
expanding field of OMV vaccines by uniting two disparate facets of bacterial contributions to medicine 
and bioengineering – probiotic bacteria and recombinant protein engineering – to create a promising 
vaccine delivery platform.  Characterization of these vaccine carriers supported the driving intention to 
harness the unique immunogenicity of probiotic bacteria as the basis for potent PLP self-adjuvancy, and 
further immunogenicity enhancement via controlled release delivery helped eliminate one of the 
primary disadvantages that plague all acellular vaccines. 
 Immunological and biomolecular characterization of the EcN OMV, both as a self-adjuvanting 
particle alone and as a vaccine carrier, revealed intriguing lessons concerning immunogenicity while 
raising additional questions.  Initially, we proposed using EcN as a source strain  due to its unique and 
potent immunostimulation; we hypothesized an OMV from EcN would be able to harness enough of this 
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potential to achieve both self-adjuvancy and immunity bias in a favorable fashion.  EcN’s biomolecular 
identity did seem to be captured by the OMVs, and all evidence does support a capacity for vaccinating 
with a TH1 bias.  Additionally, two-photon microscopy and cellular interaction studies both highlight an 
finding: the EcN OMVs are not functioning simply as a convenient way to administer bacterial 
biomolecules as a natural adjuvant, but rather are functioning as delivery vehicles that can, like 
pathogens, diffuse or be themselves delivered to immune cells and link co-stimulation with antigen 
presentation.  While the driving phenomenon behind why this is important is explored briefly in 
Appendix III, it should be noted that the phenomenon of using bacterial TLR agonists on the scale of a 
viral particle remains a insufficiently characterized phenomenon, and likely requires additional study to 
better understand just how EcN OMVs, and other OMVs, act as PLPs. 
 OMV vaccines are inherently a bacterial biotechnology, which comes with inherent advantages 
and disadvantages that were only initially explored in this work.  The immunostimulatory advantages 
have been covered in some detail; that is, bacteria are themselves adjuvants due to the nature of TLR-
directed innate immunity, which allows them to be capable of single-particle directed self-adjuvancy 
without any additional modification.  This advantage is readily coupled with the general advantage of 
working with bacteria as a common source of recombinantly engineered protein products: bacteria are 
cheap to maintain, simple to manipulate, and scale well as a biological “factory”.  But these advantages 
are balanced by some notable inconveniences of working with bacteria, primarily their use as a vector 
for non-bacterial pathogens.  While we address bacterial pathogen targets briefly in Appendix II, the 
bulk of this work used EcN OMVs as vaccines for non-bacterial targets.  This is not a straightforward 
adaptation, as whole eukaryotic antigens are rarely easily expressed in bacteria without specific 
modification, and even once optimized for such expression the lack of glycosylation and similar folding 
conditions can still result in an end product for a vaccine that is ultimately unlike the eukaryotic source.  
This is problematic for PLP vaccines in particular, as pathogen-mimetic antigen presentation assumes 
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that the antigen is itself somewhat mimetic of the pathogen’s own molecular identity.  We addressed 
this with sufficient success for our purposes by careful subunit component selection and codon 
harmonization techniques, but it is unlikely that this approach will be sufficient for all applications.  For 
this platform to truly be broadly applicable, a more straightforward platform for epitope display needs 
to be engineered to bridge the gap between bacterial expression and non-bacterial pathogen mimicry. 
 Regardless of the challenges inherent to OMV PLPs, their advantages were clearly 
demonstrated.  Cross-strain immunity against influenza is rare, and protective quantal immunity for 
allergy traditionally has required more complex delivery vectors than a simple subcutaneous injection.  
In this way, EcN OMVs as PLPs demonstrated unique capacity as a vaccine platform to do what other 
vaccines cannot.  Importantly, this success was achieved without sacrificing the inherent advantages 
discussed above purely for the sake of proving some proof-of-concept potency.  Moreover, the utility of 
the EcN OMV in achieving prophylactic allergy prevention in the peanut allergy challenge model 
supports an ambitious precedent wherein PLP vaccines are not restricted simply to improving upon 
existing modalities of vaccination, but can open up entirely new avenues of utility for vaccine technology 
for the treatment of non-pathogenic, but immunologically intricate, diseases.   
 Future work with EcN OMVs, and recombinant subunit antigen carriers derived from bacterial 
OMVs in general, should focus primarily on two avenues: addressing inherent challenges to OMV utility 
and expanding on preclinical justification for OMVs as vaccine carriers.  For the former, one unaddressed 
challenge with the EcN OMV is the stigma associated with bacterially-derived vaccines in general.  With 
public opinion overwhelmingly focused on the potential toxicity of vaccine compounds and adjuvant 
components, the likelihood of mainstream acceptance of OMV vaccines laden with biomolecules such as 
LPS is unlikely.  This work opened the door to the possibility of retaining OMV self-adjuvancy while 
removing some portion of LPS cytotoxicity, and future work to better understand and control the 
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negative effects of LPS would likely be necessary for a general OMV vaccine, likely to be classified more 
as an adjuvant than anything else, to be accepted both by the FDA and the public.  Further validation of 
OMVs as capable of inducing protective immune responses translatable to humans is also a necessary 
continuation.  For example, work already underway by our lab seeks to test the influenza EcN OMV 
vaccine in a murine and ferret influenza challenge model using species-adapted virus.  Such steps are 
the obvious path towards getting a EcN OMV vaccine technology into the pipeline for pharmaceutical 
development, and it is logical to focus on similar viral and other non-bacterial diseases at this time to 
best expand a currently empty niche in OMV vaccine technology development. 
 Ultimately, the real promise of OMVs and similar PLPs lies in their flexibility to be further 
engineered to efficiently and flexibly mimic a variety of pathogens.  The EcN source-strain in this work 
demonstrates the importance of strain selection, and a next logical step is to probe a library of similarly 
interesting bacterial immunomodulators (probiotic and otherwise) in a high-throughput fashion that can 
assess immune stimulation other than TH1 bias.  Of particular interest would be the identification of a 
bacterial source that could stimulate suppressive, regulatory immunity.  While we were able to achieve 
some form of competitive suppression using an immunotherapy adaptation of the EcN OMVs, the 
potential for bacterial diversity to provide some engineerable platform for counteracting autoimmunity 
on a larger scale remains a promising and impactful direction to expand similar efforts.  Additionally, 
further investigation into controlled release modalities on the microscale and epitope presentation on 
the molecular scale are necessary to harness the full potential of OMVs as a vaccine carrier.  Self-
adjuvancy on the nanoscale is only one piece of the complete picture of a pathogen-mimetic vaccine, 
and while arguably the one facet most capable of existing as a standalone technology, it would be a 
mistake not to find improved ways to control and apply such a potent immunomodulator. 
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 In summary, we engineered pathogen-like recombinant vaccine carriers from OMVs derived 
from probiotic EcN bacteria and used a host of tools, from heterologous antigen codon harmonization to 
microparticle controlled release, to apply this bacterial system to non-bacterial disease vaccination.  EcN 
OMVs were thoroughly assessed as potent self-adjuvanting immunomodulators for vaccine delivery 
applications, and could serve as the starting point for a platform technology uniting the molecular 
simplicity of recombinant vaccines with the molecular complexity of pathogen-mimetic immunity. 
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APPENDIX I 
ADDITIONAL AND EXPANDED MATERIALS AND METHODS 
AI.1: Preparation of OMVs.  OMVs were purified in accordance with previously established procedure89.  
Briefly, plasmid pBAD-ClyA-GFP, containing an arabinose promoter, was transformed into E. coli vesicle-
overproducing strains JC803163, JH1, and JH1-LpxM, and selected in LB-chloramphenicol or LB-
kanamycin medium, respectively.  Flasks containing 250 mL of medium were inoculated with overnight 
culture and allowed to grow until the OD600 reached ~0.5.  Protein expression was induced at this point 
by addition of L-arabinose to a final concentration of 0.2%.  Cell-free culture supernatants were 
collected 12 hours after induction and filtered through a 0.45 µm filter.  Vesicles were isolated by 
ultracentrifugation (Beckman-Coulter; Ti SW28 rotor, 26000xg, 3h, 4 ᵒC) and resuspended in PBS. 
AI.2: Microscopy.  Scanning electron microscopy was conducted on purified vesicles flash-frozen on 
copper wafers in nitrogen slush and viewed in a LEO 1550 FESEM.  Transmission electron microscopy 
was conducted on purified vesicles negatively stained with 2% uranyl acetate on 400-mesh Formvar 
carbon-coated copper grids and viewed in a FEI Tecnai F20 TEM.  Fluorescence microscopy was 
conducted on purified vesicles suspended in PBS that were placed on a glass slide, sealed with a 
coverslip, and examined using an Olympus BX41 microscope with GFP filter set. 
AI.3: Protein Analyses.  Protein concentrations in OMV and purified recombinant protein preparations 
(used as controls in the vaccine study) were quantified by the bicinchoninic-acid assay (BCA Protein 
Assay; Pierce) using BSA as the protein standard.  Fluorescence of GFP in protein and OMV samples was 
measured in a microplate spectrofluorometer (Gemini EM; Molecular Devices) using excitation and 
emission wavelengths of 481 nm and 507 nm, respectively64.  For SDS/PAGE, samples were prepared in 
sample-loading buffer containing β-mercaptoethanol and heated at 90 ᵒC for 10 min before 
electrophoresis on 10% polyacrylamide gels.  Proteins were transferred to polyvinylidine difluoride 
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membranes for Western blot analysis and probed with monoclonal mouse anti-GFP IgG (Invitrogen; 
1:2000) primary antibody, and horseradish peroxidase conjugated goat anti-mouse IgG (Jackson 
Immunoresearch; 1:10000) secondary antibody.  Membranes were developed by autoradiography with 
ECL detection reagents (GE Healthcare). 
AI.4: LPS Analyses.  Bacterial LPS concentrations were determined by measuring the presence of KDO 
according to a previously described colorimetric assay90,91.  Briefly, OMV samples (50 µL) in PBS were 
combined with 0.2 M H2SO4 (5 µL) and heated at 100 
ᵒC for 20 min.  The samples were cooled to room 
temperature for 5 min, and then 25 µL of 0.04 M NaIO4 was added to the mixture.  After 20 min of 
incubation at room temperature, 2% NaAsO2 (65 µL) was added to the sample tubes, and they were 
vortexed until the characteristic yellow color disappeared.  Thiobarbituric acid (0.3%, 250 µL) was 
added, and the samples were returned to 100 Cᵒ for 10 min, followed by the immediate addition of 
dimethyl sulfoxide (125 µL).  The samples were cooled to room temperature for 5 min, and the 
absorbance was read at 550 nm in a microplate spectrophotometer (Molecular Devices).  Calibration 
standards were prepared from KDO ammonium salt (Sigma-Aldrich). 
AI.5: Dynamic Light Scattering.  Dynamic light scattering measurements were performed with the 
Nanosizer Nano ZS (Malvern Instruments) using Dispersion Technology Software version 4.20 for data 
acquisition and analysis.  OMV samples contained 100 µg/mL total protein in 1 mL of PBS.  The refractive 
index and viscosity of water were used as parameter inputs. 
AI.6: Recombinant Protein Purification.  Cultures of E. coli DH5α transformed with pBAD-ClyA-GFP-His, 
pBAD-ClyA-His, or pBAD-GFP-His were grown in 100 mL of LB medium containing chloramphenicol.  
Protein expression was induced by the addition of L-arabinose to a final concentration of 0.2% after the 
OD600 reached ~0.5.  Bacterial cultures were harvested 4 hours after induction and lysed by treatment 
with lysozyme (1 mg/mL) and Triton X-100 (1% vol/vol).  The polyhistidine-tagged proteins in the soluble 
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fraction were purified by immobilized-metal affinity chromatography (Ni-NTA Agarose; Qiagen) 
according to the manufacturer’s instructions.  The proteins were eluted with 200 mM imidazole in a 
buffer containing 50 mM NaH2PO4 and 300 mM NaCl (pH 8.0), and they were subsequently desalted into 
PBS using PD-10 size exclusion chromatography columns (Amersham Biosciences). 
AI.7: Cell isolation and culture.  Mouse red blood cells (MRBCs) were extracted via post-euthanasia 
cardiac puncture into EDTA, then washed in PBS and stored at 4 ᵒC as a 10% solution.  For bone marrow-
derived macrophages and dendritic cells (DCs), bone marrow was obtained from mouse femurs and 
grown for 6 to 8 days in RPMI 1640 in the presence of 10% L929 conditioned medium92 and collected 7 
days later. Bone marrow-derived DCs were cultured in the presence of 20 ng/ml GM-CSF and collected 
6–8 days after culture93.  For the splenic T-cells and B-cells, spleens were harvested, mechanically 
homogenized, and filtered through a 100 µm cell strainer (Falcon). Erythrocytes were lysed with cold 
ACK lysing buffer (Cellgro) for 5 min, and the cell suspension was washed with complete medium. T cells 
were purified with enrichment columns (R& D Systems) following the manufacturer’s recommendations. 
B cells were enriched by negative selection using magnetic isolation kits, as per manufacturer’s 
instructions (Miltenyi Biotec). This resulted in cell purities of >97% as determined by flow cytometry.  
AI.8: ELISA.  Polystyrene microtiter 96-well plates (Maxisorp; Nunc Nalgene) were coated with GFP (5 
µg/ml in carbonate buffer, pH 9.6) and incubated overnight at 4 °C. Plates were blocked with 3% BSA in 
PBS containing 0.05% Tween-20 (PBST). Samples were serially diluted 2-fold in blocking buffer in a range 
of 1:200–204,800, added to the wells, and incubated for 2 hours at 37 °C. Plates were washed six times 
with PBST, and biotinylated goat anti-mouse IgG, IgM (Sigma), or monoclonal IgG1 or IgG2 (BD 
Pharmingen) were added to the wells (1 µg/ml) for 1 hour at 37 °C. Avidin-horseradish peroxidase 
(1:1000; Sigma) was then added and incubation continued for 30 min at 37 °C. After six additional 
washes with PBST, 3,3’,5,5’ tetramethylbenzidine substrate (1-Step TMB; Pierce) was added, and the 
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enzyme reaction proceeded for 20 min. The reaction was stopped with 2 M H2SO4. The absorbance was 
quantiﬁed in a microplate spectrophotometer at a wavelength of 450 nm. Serum antibody titers were 
determined by measuring the last dilution that resulted in three standard deviations above background.  
For the determination of cytokines, cells were resuspended at a concentration of 2×106 cells/well in 
medium RPMI 1640 (supplemented with FCS and antibiotics), seeded into 96-well plates and incubated 
for 48 h with 5 µg GFP. Cytokine levels were measured in the supernatants by using standard ELISA kits 
(eBioscience). 
AI.9: Hemagglutination Inhibition Assays.  Samples of A/PR8/34 and X31 influenza virus were 
inactivated in 0.02% formalin for 18h at 37°C, and then dialyzed against PBS at room temperature 
overnight.  Each virus sample was titered for stock hemagglutination units (HAs) as described 
elsewhere94 using serial two-fold dilutions of virus into freshly-drawn 1% MRBCs in PBS.  Subsequently, 
serial two-fold dilutions of serum from appropriately vaccinated mice were incubated as described 
elsewhere94 with 4 HA diluted virus samples and then exposed to 1% MRBCs in PBS.  Both assays were 
read using the teardrop method to determine the cut-off between hemagglutination and 
hemagglutination absence/inhibition. 
AI.10: Cytokine Expression Analyses.  For splenic lymphocytes, cells were stimulated overnight with 5 
µg/ml GFP, 5 ng/ml IL-2 and 10 µg/ml anti-CD28, and then cultured with brefeldin A. Cells were stained 
with fluorescent antibodies against the surface markers CD3 (clone 17A2) and CD4 (clone RM4-5), 
permeabilized, fixed and incubated with antibodies against the cytokines IFN-ɣ (clone XMG1.2) or IL-10. 
All incubations were carried out on ice for 30 min. All antibodies were purchased from BD Bioscience or 
eBioscience. For each sample, at least 50,000 cells were analyzed. The data were collected and analyzed 
using CELLQuest or FlowJo software and a FACScalibur flow cytometer (Becton Dickinson, San Jose, CA).  
For macrophages, cells were plated as above and also incubated with increasing concentrations of 
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OMVs. Sixteen hours later, brefeldin A (10 µg/ml) was added and cells were incubated for 6 additional 
hours. DCs were then collected to be stained and analyzed by flow cytometry. Prior to staining, cells 
were incubated with an anti-Fcγ III/II receptor (BD Biosciences) and 10% normal mouse serum (NMS) in 
PBS containing 0.1% BSA, 0.01% NaN3. Cells were stained with antibodies against the surface marker 
CD11c (clone 223H7), fixed in 2% paraformaldehyde, permeabilized with saponin and then incubated 
with fluorescent antibodies against the cytokines IL-12p40/p70 (clone C17.8), IL-10 (clone JES5-16E3) or 
IL-4 (clone 11B11). Incubations were carried out for 30 min on ice. All antibodies were purchased from 
BD Biosciences or eBioscience. Data was collected and analyzed as described above. 
AI.11: Inflammopathology.  Four groups of three 8-week old BALB/c mice (Charles River Laboratories) 
each were injected s.d. in each ear with 10% of the vaccine dosage described previously for PBS, EcJ 
OMVs, EcN OMVs, and EcN-LpxM OMVs.  Mice were euthanized 30 hours after injection, and their ears 
were resected and immediately fixed in 10% formalin.  Tissue samples were processed routinely for 
histopathology and stained with hematoxylin and eosin for light microscopic evaluation.  Slides were 
read and graded in a blinded fashion by a licensed pathologist.  Changes were given an overall score 
based on the grade of inflammation, edema, and tissue damage/remodeling as well as the presence or 
absence of vasculitis or vascular thrombi.   
AI.12: Phagocytosis assay.  Bone marrow-derived macrophages were plated in 6-well plates (106/well) 
for 16 hours and incubated with increasing concentrations of ClyA-GFP(+) EcN or EcJ OMVs. Two hours 
after the addition of the OMVs, plates were washed vigorously; cells were collected and analyzed by 
flow cytometry to detect internalized GFP. The data were collected using a FACScalibur flow cytometer 
and analyzed in CELLQuest software (Becton Dickinson, San Jose, CA). For each sample, at least 30,000 
cells were analyzed. 
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AI.13: T-cell Activation Analyses.  T-cell activation by stimulated DCs was assayed as described 
previously44,95.  Briefly, 96-well plates were incubated overnight with 10 µg/mL anti-mouse CD3 (clone 
145-2C11; BD Biosciences) at 4 ᵒC, after which plates were washed 3 times with complete RPMI.  T cells 
were then labeled with CFSE as described and seeded into wells from at 2X105 cell/well.  T-cells were co-
incubated with 4X104 cell/well DCs, 5 µg/mL anti-mouse CD28 (clone 37.51, Biolegend), and 1-100 
µg/mL EcJ or EcN OMVs.  Samples prepared for flow cytometry analysis incubated for 48 h at 37 ᵒC, 
incubated for 4-6 h with 25 ng/mL PMA, 1 µg/mL ionomycin, and 10 µg/mL brefeldin A, and then were 
collected and stained with IFN-γ and IL-10 (eBiosciences).  Samples prepared for ELISA analysis of culture 
supernatants were also incubated for 48h at 37 ᵒC.  Samples prepared for proliferation analysis were 
incubated at 37 ᵒC for 7 days, then trypsinized and analyzed by flow cytometry for loss of CFSE staining. 
AI.14: Two-photon imaging of lymph node tissue. BALB/c mice (n=3) were injected s.c. with 100 µg EcN 
OMVs and/or 1x106 splenic DCs, stained with DiO and DiD  respectively (Invitrogen), then euthanized 
after 4 days. After euthanasia, intact draining cervical lymph nodes were resected, placed in PBS, and 
immediately imaged via two-photon excited fluorescence microscopy on a custom setup.  
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APPENDIX II 
APPLICATION OF THE ECN OMV PLATFORM TO HETEROLOGOUS BACTERIAL ANTIGEN DELIVERY, A 
TEST CASE: MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS 
AII.1: Introduction 
 One of the great frontiers of current vaccine research is designing vaccines against complicated 
intracellular pathogens that the mammalian immune system normally has great difficulty clearing.  
Some pathogens, like the Plasmodium family of protozoan parasites, use intracellular evasion to dodge 
the immune system for fairly short amounts of time as they go through their life cycle within a 
mammalian host and cause great, often fatal, destruction in resident tissues18.  Others, like the 
Mycobacterium family (best known for causing tuberculosis in humans), use intracellular evasion inside 
macrophages themselves to lie dormant for decades before re-emerging as pathogenic19,44,96.  
Regardless of the timescale of infection, intracellular evasion is best combatted by a TH1 –biased 
immune response, and it has been theorized that a leading factor in the consistent failure of vaccines 
against pathogens such as Plasmodium and Mycobacterium is a lack of sufficient antigen-specific TH1 
immunity induction.  Therefore, we hypothesized that our EcN OMV platform may be an ideal candidate 
for vaccines against such non-viral intracellular pathogens. 
 As our preliminary model pathogen to test this application, we chose Mycobacterium avium 
subs. paratuberculosis (MAP), which causes Johne’s disease in cattle96.  Johne’s disease is essentially the 
bovine analogue of human tuberculosis (TB), thus making it a compelling and highly relevant animal 
model to study given the billions of people currently infected globally with TB and the millions of new 
chronic active cases occurring each year.  We began similarly to our approach in Chapter 3 by testing 
basic anti-antigen immune response in BALB/c mice.  For our antigen of choice, however, we took a 
slightly different approach.  Instead of simply choosing a native antigen of MAP (as we did with H1N1 
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HA), we decided to broaden the test of our platform’s recombinant subunit antigen carrier applicability 
and instead use the fusion polyprotein antigen MAP 74F96.  74F contains a segmented fusion of 
MAP3527 and MAP1519, and its inclusion in this study represents an attempt to demonstrate that the 
ClyA-antigen expression pathway can be used to enhance vaccine antigen multivalency through 
multiple-antigen inclusion.  Secondly, its choice pushes the boundaries of ClyA’s ability to externalize a 
C-terminally fused moiety – 74F is 803 amino acids long, substantially larger than the original model 
antigen GFP’s 242 amino acids.  It is highly likely that there is some upper limit to ClyA’s ability to act as 
an externalizing transporter; a larger polyprotein such as 74F may serve as a useful probing of the upper 
limit. 
 
AII.2: Materials and Methods 
AII.2.1: Construction of pBAD-ClyA-MAP74F.  The MAP74F construct was acquired from Dr. Yung-fu 
Chang and modified via site-directed mutation to insert a HindIII site at the 5’ end and an XbaI site at the 
3’ end of the MAP74 gene contained within the pMAP74F plasmid.  The plasmid was subsequently 
digested via restriction enzymes as described in AI.1 and inserted in the place of GFP in pBAD-ClyA-GFP. 
AII.2.2: Generation of EcN OMVs displaying MAP74F.  AI.1 was followed using pBAD-ClyA-MAP74F. 
AII.2.3: Vaccine studies of EcN OMVs displaying MAP74F.  2.2.2 was followed using the product of 
AII.2.2. 
AII.2.4: Assessing OMV vaccine immune response.  2.2.3-2.2.4 was followed to analyze the samples 
generated by AII.2.3. 
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AIII.3: Results and Discussion 
 Currently, we have not moved beyond the BALB/c trial, but the initial immunological data from 
that trial is promising.  The humoral (Fig. AII.1) and cellular (Fig. AII.2) data clearly indicate that despite 
the larger size and complexity of the 74F polyprotein antigen, the EcN OMV was still able to deliver it as 
an antigen and facilitate the development of antigen-specific immunity.  Of note is that by comparison 
to the data in 2.3, there was indeed a slightly diminished response relative to alum that was not seen 
using H1N1 HA in 3.3.  At this stage it is hard to determine whether that was the result of the nature of 
the 74F antigen itself, a diminished capacity of the EcN mutants to surface display the antigen via ClyA 
due to its size or some other antigen-related factor, or whether some additional factor of the trial itself 
played a role.  Perhaps most importantly, the data still indicates a strong enough response to the 74F 
antigen to be worth further investigation in a relevant animal challenge model, though future EcN OMV 
applications involving even larger antigens may require additional attention nonetheless. 
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Figure AII.1: EcN OMV carriers generate strong anti-MAP 74F humoral immunity.  (A-C) Terminal data 
points from BALB/c mice vaccinated and boosted once with antigen-normalized (or protein normalized, 
as appropriate) with EcN OMVs and controls (n=5).  (A-B) Class-specific anti-74F antibody serum titers.  
(C) Ratio of serum titers of IgG1 to IgG2.  (A-C) Alum = Alhydrogel®.  *P<0.005, **P<0.05 determined by 
Tukey’s HSD post-hoc test.  All values are given as mean + s.d.   
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Figure AII.2: EcN OMV carriers generate strong anti-MAP 74F cellular immunity.  (A-C) Terminal data 
points from BALB/c mice vaccinated and boosted once with antigen-normalized (or protein normalized, 
as appropriate) with EcN OMVs and controls (n=5).  (A) Proliferation index of antigen-restimulated 
spleen-derived T-cells harvested from end-point subjects, measured via CFSE stain.  (B-C) Cytokine 
secretion levels from cultured, antigen-restimulated spleen-derived T-cells harvested from end-point 
subjects.  (A-C) Alum = Alhydrogel®.  *P<0.005.  All values are given as mean + s.d.   
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APPENDIX III 
MODELING INTACT PATHOGEN IMMUNE CELL PRESENTATION AND POLYREACTIVE ANTIBODY 
GENERATION (USING HIV AS A MODEL) 
AIII.1: Introduction 
 Up to this point, we have demonstrated how the EcN OMV platform is an engineered vaccine 
carrier that has the demonstrated advantages of 1) TH1-biasing antigen-specific responses, and 2) 
surface displaying functionally folded exogenous antigens.  While this certainly represents a substantial 
step towards engineering a true PLP, and hopefully will provide enough advancement to spur the 
creation of several vaccines against previously out-of-reach vaccine targets, the truth is that simple 
immune modulation may not be enough for many pathogens.  Indeed, certain pathogens (and other 
non-pathogen targets) have aspects of a required immune response that defy the traditional application 
of even the ideally immunostimulatory recombinant subunit vaccine. 
 An unfortunately good example is the human immunodeficiency virus (HIV).  Despite 
monumental efforts on the part of virologists, immunologists, and epidemiologists to find a cure for the 
human immunodeficiency virus (HIV), there remains a startling absence of an effective vaccine97.   
Unsurprisingly, the very reasons that make HIV a difficult target for the immune system to handle make 
it equivalently difficult to design a vaccine against it.  HIV has a high mutagenic rate for its capsid 
proteins and, once stably integrated within T-cells, has effective mechanisms for avoiding extracellular 
contact with the immune system98.  Both of these aspects make developing a good immune response 
with neutralizing antibody populations very difficult, and this difficulty reflects back on a vaccine’s ability 
to make meaningful contributions to adaptive immunity.  Certain viral moieties, such as capsid protein 
gp120 and gp140, are decent vaccine targets due to their low mutagenicity; unfortunately, their low 
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expression level on the HIV surface membrane has led to gp120/gp140 vaccines only providing 
minimally enhanced defense99. 
 Recent work by Mouquet et al.100 may finally have given vaccine engineering the direction it 
needs, however, and in turn given us inspiration on how to further enhance our EcN OMV platform.  
Working with serum samples from HIV “controllers” with high titers of neutralizing antibodies, they 
found that polyreactive antibodies, a rare form of antibody demonstrating bispecificity for two specific 
antigens on a pathogen surface, dominated the immunoglobulin population.  These antibodies showed 
moderate affinity for gp120 as well as lower affinity for gp41, a mutagenic surface protein.  While it is 
easy to postulate that this combination of affinities would allow the antibody to superiorly neutralize 
HIV in the serum, comprehending how such an antibody, whose associated B-cells would be greatly 
disadvantaged under normal developmental conditions with the lower affinities required to generate 
polyreactivity (particularly when it is partially targeted towards a mutagenic antigen), could actually 
come to dominate polyclonal expression is an entirely different matter altogether.  That being said, the 
answer to that question may prove to be incredibly important.  If we understand how in this specific 
case certain individuals’ adaptive immunity can skew towards the dominance of polyreactive antibodies, 
we might be able to engineer a similar ability into our own vaccine carrier platform (especially given its 
strong PLP capacity).  Consequently, we used computational immunology to tackle this challenge.  
Specifically, we applied an affinity-dependent kinetic proofreading model to the unique antigen 
presentation of HIV by dendritic cells (DCs) to naïve B-cells.  We then employed kinetic Monte Carlo 
(KMC) to simulate B-cell receptor (BCR) –antigen interactions and their effect on downstream signaling 
of B-cell activation pathways.   
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AIII.2: Modeling Methods 
Our model of choice is based on a similar attempt at simplifying and quantifying the B-cell/DC 
interface and its effect on naïve B-cell molecular activation pathways used by Tsourkas et al.101  Briefly, a 
1.5x1.5x0.01 μm section of both cells is brought within 20 nm of each other and discretized into 10 nm 
blocks (representing the exclusion radius of an average cellular protein)102.  BCRs and antigen are 
randomly distributed throughout the two membranes at the beginning of the trial.  Two B-cell 
downstream signaling proteins are also included: Lyn, which is bound to the inside of the B-cell 
membrane; and Syk, which diffuses freely throughout the B-cell interior.  When BCRs come within 
binding range of opposite antigen, a reversible attachment can occur.  Should this attachment last for a 
minimum time μ, the BCR undergoes a conformational change and becomes capable of binding Lyn – 
hence the aforementioned affinity dependence.  Lyn can then phosphorylate the BCR, which can then in 
turn phosphorylate Syk.  The amount of phosphorylated Syk at the end of a B-cell/DC interaction, usually 
lasting around 100 s, is directly correlated with the extent of naïve B-cell activation, which itself directly 
determines which B-cells go on to become dominant clones in the antibody production process. 
Our first modification to the Tsourkas et al. kinetic proofreading model involves allowing for 
heteroligation of more than one antibody per BCR, a likely requirement to demonstrate any advantage 
the polyreactive BCRs (correlating to the cell’s potential polyreactive antibody production) might have in 
promoting naïve B-cell selection100.  The full schematic of the model can be found in Figure AIII.1.  
Initially, BCRs and presented antigen diffuse freely (with event probability PdiffF) in their respective 
membranes (Fig. AIII.1a).  If the antigen is within one 10 nm exclusion radius of the BCR (whose arms 
are assumed to extend up to one additional exclusion radius in any direction beyond its core), it can bind 
the BCR (PonBA1) (Fig. AIII.1b).  This complex can diffuse around the B-cell surface (PdiffC), where it might 
encounter additional diffusing antigen or Lyn (Fig. AIII.1c).  If the BCR has been in any current or 
previous BCR-Ag complex for longer than μ, then it is conformationally capable of binding the Lyn and  
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Figure AIII.1: Kinetic proofreading model for B-cell activation via BCR-antigen interactions between 
naïve B-cells and DCs.  Initially, diffusing BCRs and antigen (A) can bind if appropriately opposite each 
other (B), conformationally activating the BCR’s intracellular domain to bind Lyn (C) and be 
phosphorylated (D).  (E) Each iteration may (in the displayed case of Lyn) or may not (in the displayed 
case of Antigen 1) result in disengagement of a complex.  Finally, Syk can diffuse to (F), become 
phosphorylated by (G), and diffuse away from a phosphorylated BCR, triggering downstream signaling.  
(I) A z-axis view of the lattice set-up for the extracellular and intracellular model components.  (J) An x-y 
plane view of the pattern of gp41 (red) and gp120 (purple) HIV antigens on a simulated DC-displayed 
intact virion.  
A B C D 
E F G H 
I 
J 
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being subsequently phosphorylated on either its α or β chain (PphosIgα/β) (Fig. AIII.1d).  Additional antigen 
might also bind - in the polyreactive case, this may be a similar or different antigen (P onBA2).  Regardless 
of whether or not these additional binding events occur, both bound Lyn and antigen are capable of 
detaching (PoffBA1/Lyn) (Fig. AIII.1e).  Finally, diffusing intracellular Syk can bind phosphorylated BCRs 
(PonSyk), be phosphorylated (PphosSyk), and then detach (PoffSyk) (Fig. AIII.1f-h).   
This model was fully coded in MATLAB and was initially run on a 150x150x8 node lattice 
representing the two membranes and a 60 nm-deep portion of the intracellular compartment (Fig. 
AIII.1i).  Due to computational constraints, however, data ultimately had to be supplemented by down-
sized, representative runs on a 15x15x8 node lattice.  In the model, parameters are mapped from 
cellular concentrations and kinetic rate constants to local populations and event probabilities, 
respectively, as previously described101–103 and currently detailed in AIII.3.  The crucial parameter of μ is 
additionally dependent on the oligomerization time of the BCRs, which is affinity-dependent and 
experimentally found to be equivalent to the amount of time needed for half the total BCR population 
becoming dimerized.  Thus μ is calculated for each BCR individually by averaging the amount of time 
required to reach 50% dimerization over 10 trials101.  Additional details are provided in AIII.3. 
The second modification stems from the unique way we hypothesize HIV is presented by mature 
DCs to B-cells.  Via a recently-discovered mechanism104, HIV avoids the processing pathway of the DC’s 
phagosome and instead hijacks its parallel antigen presentation pathway to get itself externalized in an 
intact and functional form on the surface of the DCs, where it lies in wait for T-cells scanning the DC 
surface for antigen.  While this is a definite advantage for the HIV virion’s infectious capacity, it should 
also dramatically alter the way HIV antigen is presented to a B-cell.  Normally, antigen from a 
phagosome-digested pathogen would be randomly mounted on the DC surface; in this case, all HIV 
antigens would be displayed exactly as it would be encountered by the B-cells and their antibodies in 
the blood and lymph.  Concerning the model, this would mean all antigens would be essentially linked in 
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specific patterns representative of the viral surface and distributed in nodes across the DC surface (Fig. 
AIII.1j).  These patterned nodes will be modeled as arrangements of 18 gp41 and 3 gp120 each105,106.  
The details concerning this set-up are further discussed in AIII.3.  It should be noted that this primarily 
only affects the way parameters are inputted into the model; the model still remains fully capable of 
running simulations on distributed free antigen.   
Finally, we decided to approach the model using a truer application of KMC.  We hypothesized 
from the outset that while the affinity-dependent nature of the model would be essential in fully 
probing the effects of BCR heteroligation (due to the enhancement of BCR oligomerization by linked 
antigen valency), this phenomenon would likely not be a substantial enough increase in favorability to 
overcome the noise of the unbiased coin tosses used to determine events that Tsourkas et al. noted as 
problematic in differentiating between the upper end of apparent BCR-Ag affinities.  To help refine 
event tracking, we implemented the Gillespie approach to tracking transition probabilities across the 
model107,108.  It should be noted, however, that we kept the coarse-graining approach used by Tsourkas 
et al. to define the time step.  Based on empirical observation, M surface molecules involved in an 
immunological synapse are capable of M independent, random diffusive or reactive events over the 
course of 1 μs102.  Therefore, we use a time step of 1 μs to loop across M free and complexed molecules 
for the experimental duration of 100 s, only updating the transition probabilities at the beginning of 
each time step.  This coarse-graining was kept both so as to take advantage of the simplistic parameter 
mapping developed by Tsourkas et al., as well as to reduce computational time. 
 
AIII.3: Model Parameters 
AIII.3.1: Basic Model Parameters Table.  The following is a table compiled from Tsourkas et al.101 and 
represents the core parameters of the model, with key exceptions noted below: 
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Experimental 
parameter 
Measured or 
estimated value 
Simulation 
parameter 
Mapped value 
kon BCR-antigen 10
6
 M
-1
s
-1
 PonBA1, PonBA2 0.1 
Koff BCR-antigen 1-10
-3
 s
-1
 PoffBA1, PoffBA2 10
-3
-10
-6 
* 
BCR molecules/cell 10
5
 B0 400 
Antigen 
concentration 
~100 
molecules/μm 
A0 (A10+A20) ~200** 
kon Igαβ-Lyn ~10
7
 M
-1
s
-1
 PonLyn 1.0 
koff Igαβ-Lyn ~10 s
-1
 PoffLyn 0.01 
kon Igαβ-Syk ~10
7
 M
-1
s
-1
 PonSyk 1.0 
koff Igαβ-Syk ~10 s
-1
 PoffLyn 0.01 
Lyn molecules/cell 2x10
4
 L0 100 
Syk molecules/cell 4x10
5
 S0 400 
kphosIgaB ~100 s
-1
 PphosIgα/β 0.1 
kphosSyk ~100 s
-1
 PphosSyk 0.1 
Dfreemolecules 0.1 μm
2
/s PdiffF 1.0 
Dcomplexes ~0.01 μm
2
/s  PdiffC 0.1*** 
 
*For the nodal HIV antigen case, this is considered effective kinetic off rate and is increased by a factor 
of 10 for the gp41 antigen.  This is derived from Tsourkas et al.’s BCR-antigen model, which views the 
bond as a simple spring: 
 
 
where poff is the probability for a dissociative event, κ is the bond “stiffness”, and z is the intramembrane 
distance.  Assuming shedding of gp120 through the exosome navigation line with empirical 
observations105,106, we observe gp41 being “shielded” by the close proximity to unshed gp120, increasing 
the intramembrane distance and thus increasing stress on the bond (see below). 
**For the nodal HIV antigen case, A0 = 210, A10 (gp41) = 180, A20 (gp120)= 30.  These numbers are based 
on HIV virion density observations on mature dendritic cells102, coupled with a desire to normalize the 
results as close as possible to the previous A0 = 200 standard used by Tsourkas et al.
101  ~10 virions per 
1.5x1.5μm was deemed reasonably accurate, and a section of the surface was selected based on the 
curvature guidelines of the original Tsourkas et al. paper76.  Within the 30x30nm surface, a total of 21 
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gp41/120 complexes would normally exist79,80; given gp120’s shedding response to environmental 
factors such as pH, we assume a 6:1 free gp41:gp120 ratio, additionally assuming that the existing gp120 
are evenly distributed relative to the patterned distributions empirically observed of sectioned 
membranes. 
***For the nodal HIV antigen case, this is assumed to be ~0.01 due to the difference between the 
diffusion of a two-molecule complex and a single molecule multiplex with a nanoparticle (HIV diameter 
= ~120 nm, vs. a 10 nm protein); ΔD ~ 1/Δr. 
AIII.3.2: Parameter mapping. A detailed discussion of the Tsourkas et al. parameter mapping can be 
found elsewhere76.  As no additional mapping calculations are done in this paper, a brief explanation is 
provided.  Three forms of mapping are required: mapping kinetic rates to probabilities, mapping cell 
concentrations to model populations, and mapping the diffusive terms to real time.  For the first, a set 
of maximum event probabilities Pmax are arbitrarily chosen and used to obtain the relationship between 
Pmax and KA based on the number density definition of KA for a pseudo-chemical reaction.  This is then 
adjusted from 2D to 3D simply by assuming the average protein exclusion radius to be 10 nm.  For the 
second, cell concentrations are adjusted for the 1.5x1.5x0.01μm lattice using a B-cell radius of 7 nm and 
assuming the cell to be spherical.  Finally, all probabilities are normalized to the free diffusion term, 
which is set to 1.0 based on empirical observations of relative diffusion across cell surfaces within the 
time step of 1 μs. 
AIII.3.3: Affinity-variable BCR oligomerization time μ.  A key finding by Tsourkas et al.75 was that kinetic 
proofreading was best represented by including the well-known phenomenon of BCR microclustering in 
the model.  Surface protein microclustering in the immunological synapse is well-known means by which 
naïve B- and T-cells are selected to clonally expand, and there is ample evidence tying this event 
molecularly to downstream phosphorylation event enhancement.  Tsourkas et al. found that on the 
137 
 
timescale of B-cell/DC interactions, merely modeling dimerization was sufficiently accurate to model the 
more complex event of BCR microclustering of larger valencies.  While this assumption remains a good 
candidate for model improvement, we chose to keep the approximation due to the evidence on hand of 
its applicability and the simplicity it brought to a complicated molecular event.  As described in the main 
body of the text, μ was taken to be the amount of time required for 50% of the BCRs to become 
dimerized.  The dimerization event is assumed to occur whenever two conformationally active BCRs are 
adjacent to each other in the lattice.  μ was calculated for each KA of each BCR as an average of 10 
simulation trials, the results of which are tabulated here: 
BCR KA (M
-1
) μ (s) 
Generic monospecific BCR 10
5 
 15.5 
 10
6
 7.3 
 10
7
 5.8 
 10
8
 4.4 
 10
9
 3.7 
Anti-gp41 BCR, free antigen case 10
5
 17.8 
 10
9
 4.5 
Anti-gp120 BCR, free antigen case 10
5
 39.6 
 10
9
 23.5 
Polyreactive BCR, free antigen case 10
5
/10
7
 10.1 
Anti-gp41 BCR, linked antigen case 10
5
 13.5 
 10
9
 5.2 
Anti-gp120 BCR, linked antigen case 10
5
 12.7 
 10
9
 15.8 
Polyreactive BCR, linked antigen case 10
5
/10
7
 3.4 
 
 
AIII.4: Results and Discussion 
To ensure that the modifications to the model did not in some way cause it to behave differently 
than the Tsourkas et al. model under similar circumstances, we first ran the model using parameters 
reflective of a normal B-cell/DC immunological interaction.  200 non-linked antigens (designated A1) 
were distributed randomly across the simulated DC membrane surface, and allowed to interact with 400 
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BCRs over 100 s.  The downstream effects on 100 Lyn and 400 Syk molecules were also observed.  BCRs 
of varied anti-antigen KA were probed across a physiologically relevant interval (KA=10
5-109 M-1), and 
data was collected over 100 independent trials concerning final number of BCR-Ag complexes (to assess 
general BCR-Ag activity) as well as the time-evolution of phosphorylated BCR and Syk populations (pBCR 
and pSyk, respectively).  Resulting data matched well with the trends reported by Tsourkas et al.101  BCR-
Ag complex number increased regularly with KA, as would be expected (Fig. AIII.2).   Pseudo-exponential 
growth was seen in pBCR (Fig. AIII.3a) and pSyk (Fig. AIII.3b) populations, with an expected time delay 
between the two, at rates that increased with KA.  Overall, we can conclude that our model behaves 
normally relative to its foundation despite the fairly major modifications of heteroligation capacity 
incorporation and KMC transition probability application, which allows us to proceed to the more 
complicated circumstances of interest. 
Though we hypothesized the importance of intact HIV presentation to naïve B-cells by DCs 
during the T-cell independent activation interaction, it was important to first ascertain whether or not 
the capacity for increased heteroligation alone was enough to confer a crucial advantage to our 
bispecific BCR of interest.  Specifically, we were interested in a BCR representative of the antibody 
populations reported by Mouquet et al.100, where a BCR with KA = 10
5 against gp41 (designated A1) and 
KA = 10
7 against gp120 (designated A2) would be sufficient to compete in B-cell activation with a 
significantly stronger monospecific antigen.  Looking at a similar range of KA as described previously, we 
found that in the free-antigen case both monospecific antigens against the rarer gp120 as well as the 
polyreactive BCR (designated αPR) were significantly disadvantaged in BCR-Ag complex formation (Fig. 
AIII.4a).  Thus this particular circumstance did not produce results reflective of those observed in HIV 
controllers. 
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Figure AIII.2: Modeled interactions between naïve B-cell BCRs and free dendritic cell presented 
antigen.  Terminal BCR-Ag complex histograms are displayed.  Each A1 = 200, T=100s run was repeated 
100 times.  (B,C) data given as mean +/- s.d. 
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Figure AIII.3: Modeled interactions between naïve B-cell BCRs and free dendritic cell presented 
antigen.  Terminal pBCR/pSyk time-evolutions (A,B ) are displayed.  Each A1 = 200, T=100s run was 
repeated 100 times.  Data given as mean +/- s.d. 
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Figure AIII.4: Modeled interactions between naïve B-cell BCRs and HIV antigens presented on intact 
capsid predicts polyreactive antibody (αPR) competitive advantage via enhanced BCR-complexing.  
HIV antigen presentation to naïve B-cells using dispersed (A) and intact-virion linked (B) simulated 
antigen is shown.  Terminal BCR-Ag complex histogram distributions are given for dispersed (A) and 
linked (B) antigen.  As g p140 is equivalent to gp120 immunologically106, gp140 is used here for 
comparison to data from Mouquet et al.100 
B
A 
B 
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We finally assessed the effect nodal assembly of HIV antigens had on BCR activity.  Unlike the 
free antigen case, we noted marked enhancement of BCR-Ag complex formation that increased 
apparent KA of the polyreactive BCR by several orders of magnitude, similar to Mouquet et al.’s 
findings100 (Fig. AIII.4b).  Moreover, initial determination of an enhanced μ (μPR = 3.4 s) predicted a BCR 
microcomplex-enhanced increase in downstream phosphorylation reflected by the polyreactive BCR’s 
pBCR (Fig. AIII.5a) and pSyk (Fig. AIII.5b) populations eventually overtaking those of a much higher 
affinity BCR monospecific for gp41, suggesting that the true advantage of heteroligation is derived from 
enhanced BCR oligomerization. 
 
AIII.4: Conclusion 
 Herein, we successfully demonstrated the enhancement of an existing model for BCR antigen 
screening via affinity-dependent kinetic proofreading.  Collected data compared to the Tsourkas et al. 
model not only demonstrated preserved trends, but also better separation between data sets at the 
higher end of the affinity spectrum101.  This could be due to the more precise pseudo-KMC application, 
though a larger trial number would be required to fully support such a conclusion.  More importantly, 
we confirmed our hypothesis that the unique presentation of the HIV virion via mature DCs could be 
used to explain the development of polyreactive antibodies, noting the apparent importance of an 
immunoactive surface that can enhance BCR oligomerization and thus decrease the threshold BCR 
activation time μ.  This insight in particular, combined with appropriate model parameter input and 
mapping, not only helps clarify a unique component of the HIV immune response, but additionally 
promises the ability to predict and guide engineered vaccine approaches capable of triggering the same 
phenomenon. 
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Figure AIII.5: Modeled interactions between naïve B-cell BCRs and HIV antigens presented on intact 
capsid predicts polyreactive antibody (αPR) competitive advantage dependent on enhanced pBCR and 
pSyk time evolution.  HIV antigen presentation to naïve B-cells using only intact-virion linked simulated 
antigen is shown.  Data given as mean +/- s.d.  
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